

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 0 585 943 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**11.02.1998 Bulletin 1998/07**

(51) Int Cl.<sup>6</sup>: **C12N 15/12, C07K 14/73,  
A61K 35/28**

(21) Application number: **93114153.5**

(22) Date of filing: **03.09.1993**

(54) **Soluble ligands for CD40**

Lösliche Liganden für CD40

Liant soluble pour CD40

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL  
PT SE**

(30) Priority: **04.09.1992 US 940605**

(43) Date of publication of application:  
**09.03.1994 Bulletin 1994/10**

(73) Proprietor: **Bristol-Myers Squibb Company**  
**New York, N.Y. 10154 (US)**

(72) Inventors:  
• **Aruffo, Alejandro**  
**Edmonds, Washington 98020 (US)**  
• **Hollenbaugh, Diane**  
**Seattle, WA 98117 (US)**  
• **Ledbetter, Jeffrey A.**  
**Seattle, WA 98177 (US)**

(74) Representative: **Kinzebach, Werner, Dr. et al**  
**Patentanwälte**  
**Reitstötter, Kinzebach und Partner**  
**Postfach 86 06 49**  
**81633 München (DE)**

(56) References cited:  
**EP-A- 0 555 880 WO-A-93/08207**

- **J. EXPER. MED.**, vol. 175, no. 4, 1 April 1992, pages 1091-1101; **LEDERMAN S. ET AL.**: 'Identification of a novel surface protein on activated CD4+ T-cells that induces contact dependent B-cell differentiation'
- **NATURE**, vol. 357, no. 6373, 7 May 1992, LONDON, pages 80-82; **ARMITAGE R J ET AL.**: 'Molecular and biological characterisation of a murine ligand for CD40'
- **EMBO JOURNAL**, vol. 11, no. 12, December 1992, ENGLAND, pages 4313- 4321; **HOLLENBAUGH D. ET AL.**: 'The human T cell antigen gp39...'
- **CURRENT OPINION IMMUNOLOGY**, vol. 4, no. 3, June 1992, ENGLAND, pages 333-337; **NOELLE R ET AL.**: 'T helper cells'

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Printed by Jouve, 75001 PARIS (FR)

**EP 0 585 943 B1**

**BEST AVAILABLE COPY**

**Description****1. INTRODUCTION**

The present invention relates to soluble ligands for CD40 derived from human gp39 protein, which may be used in methods of promoting B-cell proliferation.

**2. BACKGROUND OF THE INVENTION****2.1. THE B-CELL ANTIGEN, CD40**

CD40 is an approximately 50 kDa glycoprotein expressed on the surface of B cells, follicular dendritic cells, normal basal epithelium, and some carcinoma and melanoma derived cell lines (Paulie *et al.*, 1985, Cancer Immunol. Immunother., **20**:23-28; Clark and Ledbetter, 1986, Proc. Natl. Acad. Sci. **83**:4494-4498; Ledbetter *et al.*, 1987, J. Immunol. **138**:788-794; Ledbetter *et al.*, 1987, in "Leukocyte Typing III," McMichael, ed., Oxford U. Press pp. 432-435; Paulie *et al.*, 1989, J. Immunol. **142**:590-595; Young *et al.*, 1989, Int. J. Cancer **43**:786-794; Galay *et al.*, 1992, J. Immunol. **149**:775). Isolation of a human cDNA encoding CD40 showed that this protein is a type I membrane protein which is significantly related to the members of the nerve growth factor receptor family (Stamenkovic *et al.*, 1989, EMBO J. **8**:1403-1410).

The role of CD40 in B cell activation is well established. Crosslinking CD40 with anti-CD40 monoclonal antibodies (mAb) induces B cell aggregation via LFA-I (Gordon *et al.*, 1988, J. Immunol. **140**:1425-1430; Barrett *et al.*, 1991, J. Immunol. **146**:1722-1729), increases serine/threonine (Einfeld *et al.*, 1988, EMBO J. **7**:711-717) and tyrosine (Uckun *et al.*, 1991, J. Biol. Chem. **266**:17478-17485) phosphorylation of a number of intracellular substrates, and provides a "competency" signal which allows B cells to proliferate and undergo class switching when stimulated with the appropriate second signal. For example, anti-CD40 mAb can synergize with phorbol myristyl acetate (PMA; Gordon *et al.*, 1987, Eur. J. Immunol. **17**:1535-1538) or anti-CD20 Mab (Clark and Ledbetter, 1986, Proc. Natl. Acad. Sci. **83**:4494-4498) to induce B cell proliferation, with IL-4 to induce B cell proliferation (Gordon *et al.*, 1987, Eur. J. Immunol. **17**:1535-1538; Rousset *et al.*, 1991, J. Exp. Med. **173**:705-710) and IgE secretion (Jabara *et al.*, 1990, J. Exp. Med. **172**:1861-1864; Rousset *et al.*, 1991, J. Exp. Med. **173**:705-710; Gascan *et al.*, 1991, J. Immunol. **147**:8-13; Zhang *et al.*, 1991, J. Immunol. **146**:1836-1842; Shapira *et al.*, 1992, J. Exp. Med. **175**:289-292) and with IL-10 and TGF- $\beta$  to induce IgA secretion by sIgD<sup>+</sup> B cells (DeFrance *et al.*, 1992, J. Exp. Med. **175**:671-682). Also, there is evidence that CD40 delivered signals are involved in modulating cytokine production by activated B cells (Cairns *et al.*, 1988, Eur. J. Immunol. **18**:349-353; Clark and Shu, 1990, J. Immunol. **145**:1400-1406).

Crosslinking of anti-CD40 mAb alone is not sufficient to induce B cell proliferation as demonstrated by the observation that anti-CD40 mAb immobilized on plastic in conjunction with IL-4 is unable to induce vigorous B cell proliferation (Banchereau *et al.*, 1991, Science **251**:70-72). However, anti-CD40 mAb immobilized on murine L cells transfected with an Fc receptor, CDw32, are able to induce B cell proliferation in the presence of IL-4 (Banchereau *et al.*, 1991, Science **251**:70-72), suggesting that a signal provided by the fibroblasts synergizes with the CD40 signal and IL-4 to drive B cell proliferation.

**2.2. THE T-CELL ANTIGEN, GP39**

Soluble forms of the extracellular domain of human CD40 such as CD40-Ig have been used to show that the CD40 ligand, gp39, is a glycoprotein of approximately 39 kDa expressed on the surface of activated CD4<sup>+</sup> murine T cells (Armitage *et al.*, 1992, Nature **357**:80-82; Noelle *et al.*, 1992, Proc. Natl. Acad. Sci. USA **89**:6550-6554). Soluble forms of gp39 have also been described and characterized (WO-A-9308207 and EP-A-555 888). Interaction with gp39 induces resting B cells to enter the cell cycle and become responsive to the growth and differentiation effects of lymphokines (Armitage *et al.*, 1992, Nature **357**:80-82; Noelle *et al.*, 1992, Proc. Natl. Acad. Sci. USA **89**:6550-6554).

Recently, a cDNA encoding murine gp39 has been isolated and shown to be functionally active when expressed as a membrane protein on transfected cells (Armitage *et al.*, 1992, Nature **357**:80-82). This cDNA encodes a 260 amino acid polypeptide with the typical features of a type II membrane protein and CV1/EBNA cells expressing murine gp39 were shown to induce murine and human B cell proliferation without additional co-stimulus.

**3. SUMMARY OF THE INVENTION**

The present invention relates for CD40 to soluble ligands derived from human gp39 protein. It is based at least in part, on the discovery, cloning, and expression of the human T cell antigen gp39, a ligand for the CD40 receptor. It is also based, in part, on the preparation of a soluble form of human gp39 which, together with a co-stimulating agent,

is able to promote B cell proliferation and differentiation.

The present invention provides for soluble forms of human gp39, in particular for an essentially purified and isolated protein comprising a sequence substantially as set forth in Figure 1 from amino acid residues 47 to 261, and further comprising an extracellular domain of a type I membrane protein, as well as for an essentially purified and isolated nucleic acid comprising a sequence substantially as set forth in Figure 1 from nucleotide residues 160 to 787, or a sequence that encodes a protein having an amino acid sequence substantially as set forth in Figure 1 from amino acid residues 47 to 261, and further comprising a sequence encoding an extracellular domain of a type I membrane protein. In a preferred, non-limiting embodiment of the invention, soluble gp39 may be produced using the expression vector CD8-gp39.

The soluble gp39 of the invention may be used, together with co-stimulating agents, to promote the proliferation of B-cells *in vivo* or *in vitro*. Such proliferation may be desirable in the treatment of conditions that would benefit from an augmented immune response, such as acquired immunodeficiency syndrome or for the generation of a cell culture system for long-term B-cell growth.

#### 4. DESCRIPTION OF THE FIGURES

Figure 1. Nucleotide and predicted amino acid sequence of human gp39 and homology to murine gp39, TNF $\alpha$  and TNF $\beta$ .

(A) The nucleotide sequence [SEQ. ID NO: 1] and translated open reading frame [SEQ. ID NO: 2] are numbered at left. Sites of potential N-linked glycosylation are marked (CHO), the predicted transmembrane domain (TM) is underlined and the two Arg residues located at the junction of the predicted transmembrane and extracellular domains are double underlined. Nucleotide and amino acid numbering is given to the left.

(B) Alignment of the predicted amino acid sequence of human gp39 (H-gp39) [SEQ. ID NO: 3], murine gp39 (M-gp39) [SEQ. ID NO: 4], human TNF $\alpha$  (H-TNF $\alpha$ ) [SEQ. ID NO: 5], and human TNF $\beta$  (H-TNF $\beta$ ) [SEQ. ID NO: 6]. Amino acids shared by at least three proteins are shown boxed; similar amino acids shared by at least three of the proteins are shown shaded.

Figure 2. Soluble recombinant human gp39 and CD72, sgp39 and sCD72. (A) The cDNA fragment encoding the extracellular domain of murine CD8 is designated mu-CD8 EC. The murine CD8 amino terminal secretory signal sequence is shown stippled. The cDNA fragment encoding the extracellular domain of human gp39 or CD72 are designated hu-gp39 EC and hu-CD72 EC, respectively. The amino acid sequences predicted at the site of fusion of the extracellular domain of murine CD8 and human gp39 [SEQ. ID NO: 7] (italic) or CD72 [SEQ. ID NO: 8] (italic) are shown below the individual diagrams. Residues introduced at the junction of the two cDNA fragments are shown underlined. The unique Bam HI restriction enzyme recognition site at the junction of the two genes is shown.

(B) Radiolabelled proteins from the supernatants of metabolically labeled mock (lanes 1 and 2) of CD8-gp39 (lanes 3 and 4) transfected COS cells were immunoprecipitated based on their interaction with the anti-murine CD8 mAb 53-6 (lanes 1 and 3) or the CD40-Ig (lanes 2 and 4) and analyzed by SDS-PAGE under reducing conditions as described in the text. The electrophoretic mobility of molecular mass standards of the indicated mass in kDa are shown to the left. (C) Radiolabelled proteins from the supernatants of metabolically labeled mock (lanes 1-4) and CD8-CD72 (lanes 5-8) transfected COS cells were recovered based on their reactivity with the anti-murine mAb 53.6 (lanes 1 and 5), the anti-CD72 mAb J3101 (lanes 2 and 6), the anti-CD72 mAb BU41 (lanes 3 and 7) and CD40-Ig (lanes 4 and 8) and analyzed by SDS-PAGE under reducing conditions as described in the text. The electrophoretic mobility of molecular mass standards of the indicated mass in kDa are shown to the left.

Figure 3. Binding of sgp39 or CD40-Ig to transfected COS cells. COS cells transfected with either a gp39 (A and B) or a CD40 (C-F) cDNA expression plasmid were examined for their ability to bind either soluble recombinant CD40 (A and B), or soluble recombinant gp39 (C and D), or the anti-CD40 mAb G28-5 (E and F) as described in the text. Phase (A, C and E) and fluorescent (B, D and F) images of representative fields are shown.

Figure 4. Characterization of the sgp39/CD40-Ig interaction. The ability of increasing concentrations of CD40-Ig (0.6  $\mu$ g/ml to 20  $\mu$ g/ml) and the control immunoglobulin fusion protein, Leu8-Ig (0.6  $\mu$ g/ml to 20  $\mu$ g/ml), to bind to immobilized sgp39 was examined by ELISA as described in the text. Likewise the ability of increasing concentrations of CD40-Ig to bind to the immobilized control fusion protein sCD72 was also examined in the same way. In both cases the sgp39 and sCD72 were immobilized on plastic which had been previously coated with the anti-murine CD8 mAb 53-6 as described in the text.

Figure 5. Activation of human peripheral blood B cell by sgp39. The ability of soluble recombinant gp39 (sgp39, hatched bars) or control soluble recombinant fusion protein (sCD72, solid bars) to stimulate the proliferation of resting human peripheral blood B cells alone or in conjunction with the anti-CD20 mAb IF5 (+ IF5) or PMA (+ PMA) was examined as described in the text, evaluated by [ $^3$ H]-thymidine incorporation and compared to that of B cells

incubated for an equivalent amount of time in the absence of exogenous stimuli (cells alone, open bars) or in the presence of either IF5 alone or PMA alone (open bars).

Figure 6. Activation of dense human tonsillar B cells by sgp39. The ability of soluble recombinant gp39 (sgp39, hatched and solid bars) to stimulate the proliferation of dense tonsillar B cells alone or in conjunction with the anti-CD20 mAb IF5 (+IF5) or PMA (+ PMA) was examined as described in the text, evaluated by [<sup>3</sup>H]-thymidine incorporation and compared to that of B cells incubated alone (cells alone, open bars) or in the presence of either IF5 alone or PMA alone (open bars). The ability of CD40-Ig (solid bars) to block the sgp39 driven B cell activation was examined at a concentration of 20 mg/ml (A) and compared to an equal concentration of an irrelevant immunoglobulin fusion protein, Leu-8-Ig (solid bars, B).

Figure 7. Amino acid [SEQ. ID NO: 9] and nucleic acid [SEQ. ID NO: 10] sequence of murine CD8.

Figure 8. Amino acid [SEQ. ID NO: 11] and nucleic acid [SEQ. ID NO: 12] sequence of human CD8.

## 5. DETAILED DESCRIPTION OF THE INVENTION

For clarity of description and not by way of limitation, the detailed description of the invention is divided into the following subsections:

- (i) cloning and expression of human gp39 (hgp39);
- (ii) preparation of soluble gp39 (sgp39); and
- (iii) utility of the invention.

### 5.1. CLONING AND EXPRESSION OF HUMAN GP39

The present invention provides for essentially purified and isolated nucleic acids encoding hgp39, for essentially purified and isolated hgp39 protein, and for methods of expressing hgp39. The complete nucleic acid sequence of hgp39 (corresponding to cDNA) and the complete amino acid sequence of hgp39 are presented in Figure 1 and contained in plasmid CDM8-hgp39, deposited with the American Type Culture Collection (ATCC) as Escherichia coli, CDM8 MC1061/p3-hgp39 and assigned accession No. 69050. An example of an expression vector that may be used to produce soluble hgp39 (shgp39) is plasmid CDM7B-shgp39 which has been deposited with the ATCC as Escherichia coli CDM7B MC1061/p3-shgp39 and assigned accession number 69049.

In particular embodiments, the present invention provides for an essentially purified and isolated nucleic acid having a sequence substantially as set forth in Figure 1, and for an essentially purified and isolated nucleic acid encoding a protein having a sequence substantially as set forth in Figure 1. The present invention further provides for an essentially purified and isolated protein having a sequence substantially as set forth in Figure 1.

The term "substantially", as used herein, indicates that the sequences set forth in Figure 1 may be altered by mutations such as substitutions, additions, or deletions that result in a molecule functionally equivalent to a protein having a sequence as set forth in Figure 1. For example, due to the degeneracy of the genetic code, the nucleic acid sequence as set forth in Figure 1 may be altered provided that the final sequence encodes a protein having the same sequence as depicted in Figure 1 or a functionally equivalent sequence; i.e., an amino acid sequence in which functionally equivalent amino acids, such as amino acids of the same group (e.g. hydrophobic, polar, basic, or acidic) are substituted into the protein.

For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and glutamine. The positively charged (basic) amino acids include arginine, lysine, and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. The proteins of the invention may also be differentially modified during or after translation, e.g. by phosphorylation, glycosylation, crosslinking, acylation, proteolytic cleavage, etc.

Genomic or cDNA clones containing hgp39-encoding sequences may be identified, for example, by synthesizing oligonucleotide probes that contain a portion of the hgp39 sequence depicted in Figure 1, and using such probes in hybridization reaction by the method of Benton and Davis (1977, Science 196:180) or Grunstein and Hogness (1975, Proc. Natl. Acad. Sci. U.S.A. 72:3961-3965). Similarly, oligonucleotide primers containing a portion of the hgp39 sequence depicted in Figure 1 may be prepared and used in polymerase chain reactions (Saiki et al., 1985, Science 230:1350-1354), using, for example, cDNA from activated T lymphocytes as template, to generate fragments of hgp39 sequence that may be pieced together to form or otherwise identify a full-length sequence encoding hgp39.

In a specific, non-limiting embodiment of the invention, cDNA encoding hgp39 may be isolated and characterized as follows. CD40-Ig, as described in Noelle et al., 1992, Proc. Natl. Acad. Sci. U.S.A. 89:6550-6554, may be modified

by the introduction of three mutations, namely L234F, L235E, and G237A, in the immunoglobulin domain, which reduce the binding to Fc receptors. The modified CD40-Ig may be purified from COS cell supernatants as described in Aruffo, 1990, *Cell* 61:1303-1313. Human gp39 cDNA may be amplified by polymerase chain reaction (PCR) from a library prepared from phytohemagglutinin-activated human peripheral blood T-cells (Camerini et al., 1989, *Nature* 342:78-82).

5 The oligonucleotide primers may be designed based on the sequence of murine gp39 (Armitage et al., 1992, *Nature* 357:80-82) and may be engineered to include cleavage sites for the restriction enzymes XbaI and HindIII, to be used in subcloning the PCR product. For example, and not by way of limitation, the following oligonucleotides may be used: 5'-GCG AAG CTT TCA GTC AGC ATG ATA GAA ACA-3' [SEQ. ID NO: 13] and 5'-CGC TCT AGA TGT TCA GAG TTT GAG TAA GCC-3' [SEQ. ID NO: 14]. Amplification may be performed with Taq polymerase and the reaction buffer recommended by the manufacturer (Perkin Elmer Cetus Corp., Norwalk, CT) using 30 cycles of the following temperature program: 2 min., 95°C; 2 min., 55°C; 3 min., 72°C. The PCR product may be digested with HindIII and XbaI and should be found to contain an internal HindIII restriction site. The resulting HindIII-XbaI fragment may then be subcloned into a suitable vector, such as, for example, the CDM8 vector. The complete gene product may be constructed by subcloning the HindIII-HindIII fragment into the vector containing the HindIII-XbaI fragment. The resulting construct

10 may then be transfected into COS cells using DEAE-dextran as described in Aruffo et al., 1990, *Cell* 61:1303-1313. Transfectants may be stained with CD40-Ig (25 µg/ml in DMEM media) followed by FITC-conjugated goat anti-human IgG Fc antibody (1:50 dilution in DMEM, TAGO, Burlingame, CA) and visualized by immunofluorescence microscopy. A clone containing the complete hgp39 sequence may be obtained by colony hybridization as described in Sambrook et al., 1989, in "Molecular Cloning: A Laboratory Manual," Cold Spring Harbor Press, Cold Spring Harbor, NY. The subcloned HindIII-HindIII fragment of the PCR product may be used to generate a <sup>32</sup>P-labelled probe by random primed polymerization. Plasmid DNA from several individual clones may be transfected into COS cells and the transfectants may be stained with CD40-Ig. Clones that give rise to positive-staining COS cell transfectants may then be further characterized by restriction fragment mapping and sequencing.

Once obtained, the hgp39 gene may be cloned or subcloned using any method known in the art. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, cosmids, plasmids, or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322; puC, or Bluescript™ (Stratagene) plasmid derivatives. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc.

30 The hgp39 gene may be inserted into a cloning vector which can be used to transform, transfect, or infect appropriate host cells so that many copies of the gene sequence are generated. This can be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified.

35 In order to express recombinant hgp39, the nucleotide sequence coding for hgp39 protein, or a portion thereof, may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted peptide/protein encoding sequence. The necessary transcription and translation signals can also be supplied by the native hgp39 gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include, but are not limited to, mammalian cell systems infected with virus (e.g. vaccinia virus, adenovirus, etc.) or transfected with plasmid expression vector; insect cell systems infected with virus (e.g. baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA. The expression elements of these vectors vary in their strengths and specificities.

45 Expression of nucleic acid sequence encoding hgp39 protein or a portion thereof may be regulated by a second nucleic acid sequence so that hgp39 protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of hgp39 may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control hgp39 expression include, but are not limited to, the SV40 early promoter region (Benoist and Chambon, 1981, *Nature* 290:304-310), the cytomegalovirus promoter, the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, *Cell* 22:787-797); the herpes thymidine kinase promoter (Wagner et al., 1981, *Proc. Natl. Acad. Sci. U.S.A.* 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, *Nature* 296:39-42); prokaryotic expression vectors such as the β-lactamase promoter (Villa-Komaroff et al., 1978, *Proc. Natl. Acad. Sci. U.S.A.* 75:3727-3731); promoter elements from yeast or other fungi such as the Gal 4 promoter or the alcohol dehydrogenase promoter; and animal transcriptional control regions, such as the immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, *Cell* 38:647-658; Adames et al., 1985, *Nature* 318:533-538; Alexander et al., 1987, *Mol. Cell. Biol.* 7:1436-1444), the beta-globin gene control region which is active in myeloid cells (Magrath et al., 1985, *Nature* 315:338-340; Kollias et al., 1986, *Cell* 46:89-94), and other tissue-specific or constitutive promoter/enhancer elements.

Recombinant hgp39 protein or peptide expressed in such systems may be collected and purified by standard

methods including chromatography (e.g. ion exchange; affinity (for example, using CD40 as ligand); and sizing column chromatography) centrifugation, differential solubility, or by any other standard technique for the purification of proteins.

According to the present invention, hgp39 protein or peptide may also be synthesized chemically using standard protein synthesis techniques.

## 5.2. PREPARATION OF SOLUBLE GP39

The present invention provides for soluble forms of human gp39. Such soluble forms of gp39 are produced by genetic engineering of hgp39-encoding nucleic acid (see Section 5.1, *supra*, and Figure 1), to produce gp39 fusion proteins which comprise the extracellular domain of gp39, which extends from amino acid residue 47 to amino acid residue 261. In addition to gp39 amino acid sequence, the fusion proteins of the invention further comprises a molecular "tag", which is an extracellular domain of a type I membrane protein and which replaces the transmembrane and cytoplasmic domains of gp39 and provides a "handle" that reacts with reagents.

Because gp39 is a type II membrane protein and is therefore oriented with a carboxy-terminal extracellular domain, the tag is desirably oriented amino-terminal to the gp39 extracellular domain (gp39 ECD). Preferably, the tag peptide contains an amino-terminal secretory signal sequence to allow export of the fusion protein.

Appropriate tag proteins are extracellular protein domains of type I membrane proteins which have well defined tertiary structures, so as to minimize the possibility of affecting the tertiary structure of gp39 ECD while increasing the likelihood of successful expression and transport. For example, an ECD protein which is known to have been incorporated into a fusion protein that was synthesized and exported in high yield from an expression system would be likely to be a suitable tag protein for soluble gp39.

Another criterion for selecting a tag protein is the availability of reagents that react with the tag protein. For example, a tag protein to which one or more monoclonal antibodies have been produced offers the advantage of providing a "handle" which may be detected or manipulated by monoclonal antibody.

Suitable tag proteins are extracellular domains of type I membrane proteins such as CD8. In preferred, specific, nonlimiting embodiments of the invention, the tag protein is the murine CD8 that comprises its extracellular domain (ECD) (described by Nakauchi et al., 1985, Proc. Natl. Acad. Sci. U.S.A. 82:5126-5130) or its human equivalent (Kavathas et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:7688). The nucleotide and amino acid sequences of murine CD8 are presented in Figure 7; the ECD is found between amino acid residues 1 and 174 (numbering from the first ATG of nucleic acid sequence), as encoded by that portion of the nucleic acid between nucleotide residues 121 and 708. The nucleotide and amino acid sequences of corresponding human CD8 are presented in Figure 8; the ECD is found between amino acid residues 1 and 161 as encoded by that portion of the nucleic acid between nucleotide residues 129 and 611.

For example, and not by way of limitation, the construct depicted in Figure 2A and described *infra* in Section 7 may be used to produce soluble gp39 (sgp39). This construct may be prepared as follows:

The ECD of hgp39 may be amplified from a cDNA library prepared from mRNA from phytohemagglutinin (PHA)-activated human peripheral blood lymphocytes. The oligonucleotide primers may be designed based on the sequence set forth in Figure 1 and may be engineered so as to place a restriction enzyme cleavage site (e.g. a BamHI cleavage site) is at the 5' end of the gene such that the reading frame may be preserved when the chimeric gene is constructed. For example, oligonucleotides which may be used are 5'-CGA AGC TTG GAT CCG AGG AGG TTG GAC AAG ATA GAA GAT-3' [SEQ. ID NO: 15] and 5'-CGC TCT AGA TGT TCA GAG TTT GAG TAA GCC-3' [SEQ. ID NO: 14]. Polymerase chain reaction may be performed using *Pfu* polymerase with buffer supplied by the manufacturer (Stratagene, LaJolla, CA) with the following temperature program: 5 min., 95°C; 2 min., 72°C, 2 min., 55°C; 40 cycles of amplification consisting of 1 min., 95°C; 2 min., 55°C; 3 min., 72°C; 10 min., 72°C. The PCR product may be digested with BamHI and XbaI and subcloned into a vector containing the gene encoding either the murine CD8 (Lyt2a) ECD or its human equivalent. The resulting construct may then be transfected into COS cells and then expressed to form sgp39, which may then be purified by absorption and elution from an affinity column which contains either CD40-Ig or an anti-murine CD8 mAb, such as 53-6, immobilized on a solid support such as sepharose beads.

It may be desirable to confirm that sgp39 fusion proteins prepared from the gp39 ECD and various tags are capable of binding to CD40. For example, and not by way of limitation, the binding of sgp39 to CD40 may be confirmed in an ELISA assay in which wells of a 96-well plate may be coated with anti-tag antibody, washed with phosphate buffered saline (PBS) containing 0.05 percent Tween-20 (TPBS) and then blocked with 1X specimen Diluent Concentrate (Genetic Systems, 225 µl/well, 2 hours, room temperature). Wells may then be washed with TPBS. Supernatants from COS cells expressing sgp39 or a negative control may be added (150 µl/well) and plates may be incubated at 4°C overnight. Wells may then be washed with TPBS and then CD40 (e.g. in the form of CD40-Ig fusion protein) or negative control protein, which may desirably be added as serial dilutions in PBS containing 1mM CaCl<sub>2</sub> and 1mM MgCl<sub>2</sub>, 20µg/ml to 0.6µg/ml, 100µl/well, 1 hr., room temp.). Wells may then be washed with TPBS and binding of CD40 to the sgp39-coated wells detected; for example, binding of CD40-Ig to sgp39-coated wells may be detected by adding per-

oxidase-conjugated goat F(ab')<sub>2</sub> anti-human IgG followed by chromogenic substrate (e.g. Genetic Systems chromogen diluted 1:100 in EIA Buffered Substrate, Genetic Systems, 100μl/well). The chromogenic reaction may be stopped after 10 minutes with the addition of Stop Buffer (Genetic Systems, 100μl/well) and the absorbance may be measured on an ELISA reader at dual wavelengths (450nm, 630nm). Alternatively, ELISA may be performed by immobilization of CD40 (e.g. CD40-Ig) on plates coated with antibody (e.g. goat anti-human Fc), and binding of sgp39 from increasing dilutions of COS cell supernatant may be detected using anti-tag antibody.

Additionally, the ability of sgp39 to bind to CD40 may be ascertained by B cell proliferation assay as follows. Peripheral blood mononuclear cells may be isolated by centrifugation through Lymphocyte Separation Medium (Litton Bionetics, Kensington, MD). Human B Lymphocytes may be enriched from PBMC by passage of cells over nylon columns (Wako Chemicals USA, Inc., Richmond, VA) and harvesting of adherent cells. The cells may then be treated with leu-leu methyl ester (Sigma, St. Louis, MO) to deplete monocytes and NK cells. The resulting cell population may be analyzed by flow cytometry on an EPICS C (Coulter Electronics, Hialeah, FLA) to determine the percentage of B cells.

Tonsillar B cells may be prepared from intact tonsils by mincing to produce a tonsillar cell suspension. The cells may then be centrifuged through Lymphocyte Separation Medium, washed twice, and then fractionated on a discontinuous Percoll gradient. Cells with a density greater than 50 percent may be collected, washed twice, and used in proliferation assays.

Measurement of proliferation may be performed by culturing B cells in quadruplicate samples in flat-bottomed 96-well microtiter plates at 5 x 10<sup>4</sup> cells per well in complete RPMI medium containing 10 percent fetal calf serum. Supernatants of COS cells expressing sgp39 or control construct, diluted 1:4, plus PMA (10ng/ml, LC Services, Woburn, MA) or 1F5 (anti-CD20, 1μl/ml), may be added to the cultures, and then B-cell proliferation may be measured by uptake of [<sup>3</sup>H]-thymidine (6.7 Ci/mmol; New England Nuclear, Boston, MA) after 5 days of culture and an overnight pulse (cells may be harvested onto glass fiber filters and radioactivity may be measured in a liquid scintillation counter). A boost in B-cell proliferation above control levels (preferably by at least about 100 percent) associated with a particular form of sgp39 indicates the sgp39 interacts with CD40 on the surface of B cells and is biologically active.

The present invention provides for an essentially purified and isolated nucleic acid comprising a sequence substantially as set forth in Figure 1 from nucleotide residues 160 to 787, which is used toward the production of the fusion proteins of the invention. Accordingly, the present invention also provides for an essentially purified and isolated nucleic acid comprising a sequence substantially as set forth in Figure 1 from nucleotide residues 160 to 787 and further comprising a sequence encoding an extracellular domain of a type I membrane protein; in preferred embodiments, this other protein is murine or human CD8 protein. In a specific, nonlimiting embodiment of the invention, the extracellular domain of this other protein is the extracellular domain of murine or human CD8 from amino acid residues 1 to 174 and 1 to 161, respectively as encoded by the sequence between nucleotides 121-708 as depicted in Figure 7 and residues 129-611 in Figure 8. In a preferred, specific, nonlimiting embodiment of the invention, this essentially purified and isolated nucleic acid is contained in plasmid CDM7B<sup>+</sup> MC1061/p3-shgp39 as deposited with the ATCC and assigned accession number 69049. The present invention further provides for proteins encoded by such nucleic acids.

For example, the present invention provides for an essentially purified and isolated protein comprising a sequence substantially as set forth in Figure 1 from amino acid residues 47-261, and further comprising an extracellular domain of a type I membrane protein. In preferred embodiments, this other protein is murine or human CD8 protein, and in a specific, nonlimiting embodiment of the invention, the extracellular domain of this other protein is the extracellular domain of murine or human CD8 from amino acid residues 1-174 and 1-161, respectively. In a preferred, specific, nonlimiting embodiment of the invention, the essentially purified and isolated protein is as produced by expression of plasmid CDM7B<sup>+</sup> MC1061/p3-shgp39, as deposited with the ATCC and assigned accession number 69049.

### 5.3. UTILITY OF THE INVENTION

The present invention provides for a method of promoting the proliferation and/or differentiation of CD40-bearing cells comprising exposing the cells to an effective concentration of a soluble hgp39 protein, described in Section 5.2, supra.

In preferred embodiments, the invention is used to promote the proliferation and/or differentiation of B-cells which may have been activated prior to exposure to the soluble gp39 protein, concurrently with exposure to soluble gp39 protein or, less preferably, after exposure to soluble gp39 protein, wherein the soluble gp39 protein is still present. Activation of B-cells may be accomplished by any method known in the art, including exposure to costimulating agents including, but not limited to, anti-immunoglobulin antibody, antibody directed toward a B-cell surface antigen (e.g. CD20), phorbol myristyl acetate (PMA), ionomycin, or soluble or surface-bound cytokines (e.g. IL-4).

An effective concentration of soluble gp39 is defined herein as a concentration which results in an increase in activated B-cell proliferation of at least one hundred percent relative to the proliferation of activated B-cells that are not exposed to gp39 or other mediators of B-cell proliferation (see, for example, Section 5.1 supra and Section 7.1.3

infra). For example, and not by way of limitation, a concentration of between about 0.005-2.5 µg/ml, and most preferably about 0.1-0.25 µg/ml may be used.

As set forth in U. S. Serial No. 708,075, which is incorporated by reference in its entirety herein, the soluble gp39 proteins of the invention have a number of uses, including in vitro and in vivo uses.

According to one embodiment of the invention, soluble gp39 may be used to produce an in vitro cell culture system for long-term B-cell growth. This may be particularly useful in the preparation of antigen-specific B-cell lines.

In another in vitro embodiment, soluble gp39 may be used to identify or separate cells which express CD40 antigen and/or to assay body fluids for the presence of the CD40 antigen which may or may not be shed. For example, the binding of soluble gp39 to CD40 antigen may be detected by directly or indirectly labeling the soluble gp39, for example, by incorporating radiolabel or chromogen into the soluble gp39 protein (direct labeling) or via anti-gp39 antibody (indirect labeling). In this manner, soluble gp39 may be used diagnostically in vitro to identify CD40 antigen as expressed in tumors, malignant cells, body fluids, etc.

In related embodiments, directly or indirectly labeled soluble gp39 may be used in vivo to image cells or tumors which express the CD40 antigen.

In various other in vivo embodiments, soluble gp39 may be used to increase an immune response, for example, by acting, effectively, as a type of "adjuvant" to increase an immune response to a vaccine. Alternatively, soluble gp39 may be used to increase the immune response of an immunosuppressed individual, such as a person suffering from acquired immunodeficiency syndrome, from malignancy, or an infant or elderly person.

In still further embodiments of the invention, soluble gp39 may be chemically modified so that cells that it binds to are killed. Since all B-cells express CD40, this approach would result in suppression of the immune response. For example, a cytotoxic drug linked to soluble gp39 may be used in vivo to cause immunosuppression in order to cross histocompatibility barriers in transplant patients; alternatively, these modified ligands may be used to control autoimmune diseases.

In further embodiments, soluble gp39 may be used to promote the proliferation and/or differentiation of CD40-bearing cells that are not B cells, for example, sarcoma cells, as a means of directly treating malignancy or as an adjunct to chemotherapy.

The present invention further provides for the production of anti-hgp39 antibodies, polyclonal or monoclonal, using standard laboratory techniques.

The present invention also provides for pharmaceutical compositions that comprise a therapeutically effective concentration of a soluble gp39 as described in Section 5.2, supra, in a suitable pharmacological carrier.

Such pharmaceutical compositions may be administered to a subject in need of such treatment by any suitable mode of administration, including but not limited to intravenous, local injection, subcutaneous, intramuscular, oral, intranasal, rectal, vaginal, intrathecal, etc.

## 6. EXAMPLE: THE HUMAN T CELL ANTIGEN GP39, A MEMBER OF THE TUMOR NECROSIS GENE FAMILY, IS A LIGAND FOR THE CD40 RECEPTOR ON B CELLS

### 6.1. MATERIALS AND METHODS

CD40-Ig, as described in Noelle et al., 1992, Proc. Natl. Acad. Sci. U.S.A. 89:6550-6554, was modified by the introduction of three mutations, namely L234F, L235E, and G237A, in the immunoglobulin domain to reduce the binding to Fc receptors. The modified CD40-Ig was purified from COS cell supernatants as previously described (Aruffo et al., 1990, Cell 61:1303-1313). Human gp39 CDNA was amplified by polymerase chain reaction (PCR) from a library prepared from mRNA isolated from PHA-activated human peripheral blood T-cells (Camerini et al., 1989, Nature 342:78-82). The oligonucleotide primers were designed based on the sequence of the murine gp39 (Armitage et al., 1992, Nature, 357:80-82) and included sites for the restriction enzymes Xba I and HindIII to be used in subcloning the PCR product. The oligonucleotides used were: 5'-GCG AAG CTT TCA GTC AGC ATG ATA GAA ACA-3' [SEQ. ID NO: 13] and 5'-CGC TCT AGA TGT TCA GAG TTT GAG TAA GCC-3' [SEQ. ID NO: 14]. Amplification was performed with Taq polymerase and the reaction buffer recommended by the manufacturer (Perkin Elmer Cetus Corp., Norwalk, CT) using 30 cycles of the following temperature program: 2 min., 95°C; 2 min., 55°C; 3 min., 72°C. The PCR product was digested with HindIII and XbaI and was found to contain an internal HindIII restriction site. The HindIII-XbaI fragment was subcloned into the CDM8 vector. The complete gene product was constructed by subcloning the HindIII-HindIII fragment into the vector containing the HindIII-XbaI fragment. The resulting construct was transfected into COS cells using DEAE-dextran as described in Aruffo et al., 1990, Cell 61:1303-1313). Transfectants were stained with CD40-Ig (25 µg/ml in DMEM media) followed by FITC-conjugated goat anti-human IgG Fc antibody (1:50 dilution in DMEM, TAGO, Burlingame, CA) and visualized by immunofluorescence microscopy. The complete human gp39 was obtained by colony hybridization as described (Sambrook et al., 1989, "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). The subcloned HindIII-HindIII fragment of the PCR product was



used to generate a  $^{32}\text{P}$ -labeled probe by random primed polymerization. Plasmid DNA from three individual clones were transfected into COS cells and cells were stained with CD40-Ig. One clone, clone 19, was positive by this criteria and was used in the remainder of the study. The sequence was determined by dideoxy sequencing using Sequenase<sup>TM</sup> (United States Biochemical Co., Cleveland, OH)

## 6.2. RESULTS

A cDNA encoding the human gp39 was amplified from a cDNA library prepared from mRNA isolated from PHA activated human peripheral blood T cells by the polymerase chain reaction (PCR) using synthetic oligonucleotides based on the murine gp39 sequence (Armitage *et al.*, 1992, Nature 357:80-82). The PCR product was subcloned into the expression vector CDM8 (Seed, 1987, Nature 329:840-842). COS cells transfected with the CDM8-gp39 plasmid produced protein which bound to CD40-Ig (Noelle *et al.*, 1992, Proc. Natl. Acad. Sci. U.S.A. 89:6550-6554). A complete human gp39 gene was isolated by colony hybridization from the same cDNA library that was used for the PCR amplification of gp39 using the subcloned PCR product as a probe. A number of positive clones were isolated and analyzed by restriction enzyme digestion. DNA corresponding to those clones containing the largest inserts, 1.8-1.5 kb, were transfected into COS cells and their ability to direct the expression of a CD40-Ig binding protein examined. One such clone was positive by this criteria and was analyzed further and is referred to hereafter as human gp39. Immunoprecipitation of cDNA-encoded human gp39 protein from transfected COS cells using CD40-Ig showed a single band corresponding to a molecular mass of about 32-33 kDa. The COS-cell derived protein is smaller than we had expected based on our previous studies of murine gp39, however, we have observed in many instances that the apparent molecular masses of a number of different T cell surface proteins obtained from COS cell transfectants are smaller than those obtained from T cells (Aruffo and Seed, 1987, EMBO J. 11:3313-3316; Aruffo *et al.*, 1991, J. Exp. Med. 174:949-952). These differences in size may be the result of incomplete glycosylation of the proteins by COS cells.

The human gp39 cDNA is about 1.8 kb in length and encodes a polypeptide of 261 amino acids (aa) with a predicted molecular mass of about 29 kDa consisting of a 22 amino acid amino-terminal cytoplasmic domain, a 24 amino acid hydrophobic transmembrane domain and a 215 amino acid carboxyterminal extracellular (EC) domain with one N-linked glycosylation site (Asn-X-Ser/Thr) in the EC and one in the cytoplasmic domain (nucleotide sequences corresponding to coding sequence and the predicted amino acid sequence are shown in Figure 1a). The expected orientation of the protein, with an extracellular carboxy-terminus, classifies it as a type II membrane protein and the difference between the predicted and observed molecular mass suggest that it undergoes posttranslational modifications, most likely the addition of carbohydrate groups.

The predicted amino acid sequence of human gp39 was compared with those in the National Biomedical Research Foundation (NBRF) database using the FASTP algorithm and found to have significant homology with tumor necrosis factor (TNF)  $\alpha$  (Gray *et al.*, 1984, Nature 312:721-724) and  $\beta$  (Pennica *et al.*, 1984, Nature 312:724-729; Wang *et al.*, 1985, Science 228:149-154) (Figure 1b). The extracellular domain of gp39 is as closely related to TNF  $\alpha$  and  $\beta$ , having about 25% homology with each, just as TNF  $\alpha$  and TNF  $\beta$  share about 30% homology (Pennica *et al.*, 1984, Nature 312:724-729).

## 6.3. DISCUSSION

The ability of the surface receptor CD40 to deliver signals to the B cell has been established using monoclonal antibodies (Clark and Ledbetter, 1986, Proc. Natl. Acad. Sci. 83:4494-4498; Gordon *et al.*, 1987, Eur. J. Immunol. 17:1535-1538). To further study the role of CD40, a cDNA encoding the CD40 ligand from a human source has been isolated and characterized.

Isolation of a cDNA clone encoding human gp39 showed that this type II membrane protein is closely related to TNF  $\alpha$  (Gray *et al.*, 1984, Nature 312:721-724) and  $\beta$  (Pennica *et al.*, 1984, Nature 312:724-729; Wang *et al.*, 1985, Science 228:149-154). TNF  $\alpha$  and  $\beta$  are pleiotropic cytokines that exist predominantly as secreted proteins.

## 7. EXAMPLE: EXPRESSION OF A SOLUBLE FORM OF GP39 WITH B CELL CO-STIMULATORY ACTIVITY

### 7.1. MATERIALS AND METHODS

#### 7.1.1. CONSTRUCTION, CHARACTERIZATION, AND PREPARATION OF A SOLUBLE GP39 CHIMERA

The extracellular domain of the human gp39 was amplified from the cDNA library prepared from mRNA from PHA activated human peripheral blood lymphocytes. The oligonucleotide primers were designed based on sequence information obtained from the PCR product described above and were designed to place a BamHI site at the 5' end of the gene such that the reading frame would be preserved when the chimeric gene was constructed. The oligonucleotides

used were 5'-CGA AGC TTG GAT CCG AGG AGG TTG GAC AAG ATA GAA GAT-3' [SEQ. ID NO: 15] and 5'-CGC TCT AGA TGT TCA GAG TTT GAG TAA GCC-3' [SEQ. ID NO: 14]. The PCR was performed using the Pfu polymerase with the buffer supplied by the manufacturer (Stratagene, La Jolla, CA) with the following temperature program: 5 minutes, 95°C; 2 minutes, 72°C; 2 minutes, 55°C; 40 cycles of amplification consisting of 1 minute, 95°C; 2 minutes, 55°C; 3 minutes, 72°C; 10 minutes, 72°C. The PCR product was digested with BamHI and XbaI and subcloned in a vector containing the gene encoding the murine CD8 (Lyt2a) extracellular domain with a BamHI restriction site generated by PCR. Similarly, the gene encoding the extracellular domain of human CD72 was generated by PCR to contain a BamHI restriction site and subcloned in the CD8-containing vector in the same manner.

The ability of COS cells to express and export shgp39 and sCD72 was tested. First, COS cells were transfected using DEAE-dextran. One day after transfection, cells were trypsinized and replated. One day later, cells were fixed with 2% formaldehyde in PBS (20 min., room temp.) and permeabilized with 2% formaldehyde in PBS containing 0.1% Triton X-100. (20 min., room temp.). Cells transfected with sgp39 were stained with CD40-Ig (25 µg/ml in DMEM, 30 min., room temp.) followed by FITC-conjugated goat anti-human Fc antibody (TAGO, Burlingame, CA) diluted 1:500 in DMEM. Cells transfected with sCD72 were stained with the anti-CD72 antibody BU40 (The Binding Site, Birmingham, UK) followed by FITC-conjugated goat anti-mouse Fc antibody (TAGO, Burlingame, CA) diluted 1:500 in DMEM.

COS cells transfected with the shgp39 or sCD72 constructs or vector alone (mock) were grown overnight in Cys- and Met- free DMEM to which [<sup>35</sup>S]-L-methionine and [<sup>35</sup>S]-L-cysteine had been added (Tran[<sup>35</sup>S]-label, ICN, Costa Mesa, CA, 27 µCi/ml). Supernatants were harvested and centrifuged at 1krpm for 10 minutes. Fusion proteins were recovered from the supernatant using CD40-Ig, 53-6 (anti-murine CD8) plus goat anti-rat Fc, BU40, BU41 (The Binding Site, Birmingham, UK) plus goat anti-mouse IgM Fc, or J3.101 (AMAC Inc., Westbrook, ME). Goat antibodies were purchased from Organon Teknika Co., West Chester, PA. For each sample, 1 ml of supernatant, 75 µl Protein A-sepharose (Repligen, Cambridge, MA) and the precipitating agent(s) were mixed and incubated at 40°C for 2 hr. The sepharose was washed extensively with PBS containing 0.01% NP-40 and resuspended in loading buffer containing 5% β-mercaptoethanol. Proteins were subjected to SDS-PAGE in a 8% polyacrylamide gel. The gel was fixed, dried and exposed to film. COS cell supernatants containing shgp39 or sCD72 were generated by transfection of COS cells. One day after transfection, cell media was changed to DMEM containing 2% FBS. Supernatants were harvested eight days after transfection.

#### 7.1.2. BINDING ASSAYS

The binding of hgp39 and CD40 to the soluble forms of their respective ligands was tested by staining of transfected COS cells. COS cells were transfected with CD40, hgp39 or vector alone (mock) using DEAE-dextran. One day after transfection, cells were trypsinized and replated. Cells were stained on the following day. Cells expressing gp39 or mock transfected cells were stained with CD40-Ig (25 µg/ml) followed by FITC-conjugated goat and-human Fc. Cells expressing CD40 were stained by incubation with COS cell supernatants containing shgp39 followed by mAb 53-6 (anti-murine CD8, 2.5 µg/ml) then FITC-conjugated goat anti-rat Fc (Organon Teknika Co., West Chester, PA, 1.5 µg/ml). As controls, COS cells expressing CD40 were stained with FITC-conjugated G28-5 (anti-CD40) or using COS cell supernatants containing sCD72. All incubations were done at room temperature in PBS containing 1 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub> and 2% FBS and the same buffer was used for all washes. Following staining, cells were fixed with 1% para-formaldehyde in PBS.

The binding of shgp39 to CD40-Ig was investigated in an ELISA assay. Wells of a 96-well plate (Immunoion-2, Dynatech) were coated with 53-6 antibody (anti-murine CD8, 10 µg/ml, 100 µl/well, 50 mM sodium bicarbonate, pH 9.6, 1 hour, room temperature). Wells were washed with phosphate buffered saline containing 0.05% Tween-20 (TPBS) and blocked with 1X Specimen Diluent Concentrate (Genetic Systems, 225 µl/well, 2 hours, room temperature). Wells were washed (TPBS). Supernatants from COS cells expressing either sgp39 or sCD72 were added (150 µl/well) and plates were incubated at 4°C overnight. Wells were washed (TPBS) and fusion proteins CD40-Ig or Leu8-Ig were added (serially diluted in PBS containing 1 mM CaCl<sub>2</sub> and 1 mM MgCl<sub>2</sub>, 20 µg/ml to 0.6 µg/ml, 100 µl/well, 1 hr., room temp.) Wells were washed (TPBS) and peroxidase-conjugated goat F(ab')<sub>2</sub> anti-human IgG was added to each well (TAGO, Burlingame CA, 1:5000 dilution in 1X Specimen Diluent, 100 µl/well, 1 hr., room temp.) Wells were washed (TPBS) and chromogenic substrate was added (Genetic Systems chromogen diluted 1:100 in EIA Buffered Substrate, Genetic Systems, 100 µl/well). The reaction was stopped after 10 minutes with the addition of Stop Buffer (Genetic Systems, 100 µl/well) and the absorbance was measured on an ELISA reader at dual wavelengths, namely 450 or 630nm. Additionally, the ELISA was performed by immobilization of CD40Ig on plates coated with goat anti-human Fc. Binding of shgp39 from increasing dilutions of COS cell supernatants was detected using 53-6 Mab followed by FITC conjugated goat anti-rat Fc. Fluorescence was measured on a microplate reader.

### 7.1.3. B CELL PROLIFERATION ASSAYS

Peripheral blood mononuclear cells (PBMC) were isolated by centrifugation through Lymphocyte Separation Medium (Litton Bionetics, Kensington, MD). Human B lymphocytes were enriched from PBMC by passage of cells over nylon columns (Wako Chemicals USA, Inc., Richmond, VA) and harvesting of adherent cells. These cells were then treated with leu-leu methyl ester (Sigma, St. Louis, MO) to deplete monocytes and NK cells. The resulting cell population was analyzed by flow cytometry on an EPICS C (Coulter Electronics, Hialeah, FLA) and consisted of 50% human peripheral B cells.

Tonsillar B cells were prepared from intact tonsils by mincing to give a tonsillar cell suspension. The cells were then centrifuged through Lymphocyte Separation Medium, washed twice and fractionated on a discontinuous Percoll (Sigma, St. Louis, MO) gradient. Cells with a density greater than 50% were collected, washed twice and used in proliferation assays.

COS cells transfected with the gp39 construct or vector alone (mock-COS) were harvested from tissue culture plates with EDTA, washed twice with PBS, suspended at  $5 \times 10^6$  cells/ml and irradiated with 5000 rads from a  $^{137}\text{Cs}$  source. COS cells were used at a ratio of 1:4 ( $1 \times 10^4$  COS cells vs.  $4 \times 10^4$  B cells) in proliferation assays.

Measurement of proliferation was performed by culturing cells in quadruplicate samples in flat-bottomed 96-well microtiter plates at  $5 \times 10^4$  cells per well in complete RPMI medium containing 10% FCS. Reagents used were IF5 (anti-CD20, 1  $\mu\text{g/ml}$ ); PMA (10 ng/ml, LC Services Woburn, MA); G28-5 (anti-CD40, 1  $\mu\text{g/ml}$ ); CD40Ig (5  $\mu\text{g/ml}$  in assays of peripheral blood B cells, 20  $\mu\text{g/ml}$  in assays of tonsillar B cells); supernatants of COS cells expressing shgp39 or sCD72 (diluted 1:4). Cell proliferation was measured by uptake of [ $^3\text{H}$ ]thymidine (6.7 Ci/mmol; New England Nuclear, Boston, MA) after 5 days of culture and an overnight pulse. Cells were harvested onto glass fiber filters and radioactivity was measured in a liquid scintillation counter.

## 7.2. RESULTS

### 7.2.1. PREPARATION AND CHARACTERIZATION OF THE RECOMBINANT GP39 AS A CHIMERIC FUSION PROTEIN

Because gp39 is a type II membrane protein, and type II membrane proteins are oriented with a carboxy-terminal EC domain, a fusion construct was designed such that a tag polypeptide was placed amino-terminal to the EC portion of the protein, replacing the trans-membrane and cytoplasmic domains of the surface protein. The tag polypeptide should contain an amino-terminal secretory signal sequence to allow export of the fusion protein. We chose the murine CD8 EC domain (Nakauchi *et al.*, 1985, Proc. Natl. Acad. Sci. U.S.A. 82:5126-5130) as our tag polypeptide to construct our fusion proteins of type II membrane proteins for four reasons: (i) the use of an intact extracellular protein domain with a well defined tertiary structure as the tag polypeptide minimizes the chances that the tag polypeptide will affect the tertiary structure of the surface protein to which it is fused while maximizing the likelihood that the fusion protein will be expressed and exported, (ii) a previously studied CD8 Ig chimera demonstrated that CD8 fusion proteins are produced and exported by COS cells in high yield, (iii) a large number of mAb directed to CD8 are available and can be used to manipulate the recombinant CD8 fusion proteins; and (iv) the interaction between murine CD8 and human MHC I is not detectable. To generate the CD8-gp39 fusion gene, shgp39, a cDNA fragment encoding the EC domain of murine CD8 was fused with a cDNA fragment encoding the EC domain of gp39 as described in the Materials and Methods (Figure 2a). The shgp39 protein was prepared by transient expression in COS cells and recovered from COS cell supernatants with anti-CD8 mAb or with a soluble recombinant CD40-Ig chimera which we used in our earlier murine gp39 studies (Figure 2b). The shgp39 protein has a molecular mass of about 50 kDa (Figure 2b) when analyzed by SDS-PAGE under reducing conditions. Experimental results indicate that shgp39 forms dimers and trimers in solution.

As a control, a chimeric gene encoding a soluble recombinant form of the B cell antigen CD72 (Von Hoegen *et al.*, 1990, J. Immunol. 144:4870-4877), another type II membrane protein, was constructed (Figure 2a). The sCD72 protein was also produced by transient expression in COS cells and recovered from COS cell supernatants with anti-CD8 mAb or with three anti-CD72 mAb tested, but not with the CD40-Ig fusion protein (Figure 2c).

To further characterize the interaction between CD40 and the soluble recombinant hgp39, COS cells were transfected with a cDNA encoding the full length CD40 protein (Stamenkovic *et al.* 1989, EMBO J. 8:1403-1410) and their ability to bind to shgp39, sCD72, and anti-CD40 mAb examined by fluorescence microscopy. Both the shgp39 and the anti-CD40 mAb bound to the transfectants while sCD72 did not (Figure 3). In addition, COS cells were transfected with a cDNA encoding the surface bound gp39 and their ability to bind to CD40-Ig (Noelle *et al.*, 1992, Proc. Natl. Acad. Sci. U.S.A. 89:6550-6554) or an irrelevant Ig fusion protein, Leu8-Ig (Aruffo *et al.* 1992, Proc. Natl. Acad. Sci. U.S.A. 89:2292-2296), examined. CD40-Ig, but not Leu8-Ig, bound to gp39 expressing COS cells (Figure 3). In parallel experiments, shgp39 and CD72 were immobilized in the wells of a 96 well microtiter dish via an anti-CD8 mAb and their

binding to increasing concentrations of CD40-Ig or a control immunoglobulin fusion protein, Leu8-Ig; examined. The binding of CD40-Ig to immobilized shgp39 was saturable, while CD40-Ig did not bind to sCD72 and Leu8-Ig did not bind to shgp39 (Figure 4).

Resting, human peripheral blood B cells were also incubated with the soluble recombinant hgp39, shgp39, or a control soluble fusion protein, sCD72, in the absence or presence of anti-CD20 mAb or PMA. Although very weak proliferation was observed with shgp39 alone, shgp39 induced vigorous B cell proliferation when either anti-CD20 mAb or PMA was present (Figure 5). B cell proliferation was not observed with sCD72, anti-CD20 mAb or PMA alone or with sCD72 in conjunction with anti-CD20 mAb or PMA (Figure 5).

In parallel experiments resting, dense human tonsillar B cells were prepared as described in the Materials and Methods section and their ability to proliferate in response to shgp39 and sCD72 examined (Figure 6). As had been seen with peripheral blood B cells, tonsillar B cells proliferated weakly in response to shgp39 but showed strong proliferation when incubated with shgp39 in the presence of the anti-CD20 mAb IF5 or PMA. No significant proliferation over background levels was observed when the cells were incubated with sCD72 alone or in the presence of the IF5 mAb or PMA. To examine the specificity of the shgp39 driven activation response the ability of CD40-Ig to block the shgp39/IF5 or shgp39/PMA driven B cell proliferation was examined. CD40-Ig was able to reduce the shgp39 driven B cell activation (~20 µg/ml gave ~50% inhibition, Figure 6A) while a control fusion protein Leu8-Ig had no effect (Figure 6B).

### 7.3. DISCUSSION

It has been reported that purified murine splenic B cells and human tonsillar B cells proliferate when incubated with CV1/EBNA cells expressing murine gp39 in the absence of co-stimulus (Armitage et al., 1992, Nature 357:80-82). Based on these data it had been thought that gp39 is directly mitogenic for B cells. To determine if gp39 binding to CD40 is able to stimulate resting B cells to proliferate in the absence of other co-stimulatory signals, and the effect of the fibroblast cells in the stimulation, the proliferation of B cells in response to COS cells expressing shgp39 was tested.

shgp39 was only able to induce resting B cells, isolated from either peripheral blood or tonsils, to proliferate in conjunction with co-stimuli such as anti-CD20 mAb or PMA. As had been observed with hgp39-expressing COS cells, shgp39 driven B cell activation could be inhibited with CD40-Ig but not with an irrelevant Ig fusion protein.

The development of factor dependent, long term B cell cultures has important applications for the study of B cell growth and differentiation and the development of antigen-specific B cell lines (Tisch et al., 1988, Immunol. Today 9: 145-150). Experiments with anti-CD40 mAb showed that CD40 signals can synergize with other co-stimulatory signals such as those delivered by anti-CD20 mAb to drive B cell proliferation and that treatment of B cells with anti-CD40 mAb induces a state of B cell "alertness" which allows them to respond more readily to subsequent activation signals. The ability of shgp39 to stimulate B cell proliferation in conjunction with anti-CD20 mAb or PMA suggests that it may be used to create *in vitro* systems for long term B cell growth.

It is interesting to note that the CD40-Ig fusion protein and the shgp39 fusion described here can be used to, respectively, either inhibit or stimulate the CD40 response in B cells and thus are useful tools in the study of B-cell/T cell interactions and in clinical applications.

### 8. DEPOSIT OF MICROORGANISMS

The following were deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, 20852:

|   | ATCC Designation |
|---|------------------|
| <u>Escherichia coli</u> CDM7B <sup>+</sup> MC1061/p3-shgp39 | 69049            |
| <u>Escherichia coli</u> CDM8 MC1061/p3-hgp39                | 69050            |

The present invention is not to be limited in scope by the microorganisms deposited since the deposited embodiments are intended as illustrations of single aspects of the invention and any microorganisms which are functionally equivalent are within the scope of the invention.

The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention, and any clones, DNA or amino acid sequences which are functionally equivalent are within the scope of the invention. Indeed, various modifications of the invention in addition to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

It is also to be understood that all base pair sizes given for nucleotides are approximate and are used for purposes

of description.

Various publications have been cited herein, the contents of which are hereby incorporated by reference in their entirety.

5 SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT:

10

- (A) NAME: Bristol-Myers Squibb Company
- (B) STREET: 345 Park Avenue
- (C) CITY: New York
- (D) STATE: New York
- 15 (E) COUNTRY: U.S.A.
- (F) ZIP: 10154

(ii) TITLE OF INVENTION: SOLUBLE LIGANDS FOR CD40

20

(iii) NUMBER OF SEQUENCES: 15

(iv) CORRESPONDENCE ADDRESS:

25

- (A) ADDRESSEE: Reitstötter, Kinzebach & Partner
- (B) STREET: Sternwartstraße 4
- (C) CITY: Munich
- (D) STATE: Bavaria
- (E) COUNTRY: Germany
- 30 (F) ZIP: D-81679

(v) COMPUTER READABLE FORM:

35

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release 1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

40

- (A) APPLICATION NUMBER:
- (B) FILING DATE: September 03, 1993
- (C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

45

- (A) NAME: Kinzebach, Werner, Dr.
- (B) REGISTRATION NUMBER: 3379
- (C) REFERENCE/DOCKET NUMBER: M/34164

50

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: (089) 98 06 56
- (B) TELEFAX: (089) 98 73 04
- 55 (C) TELEX: 5215208

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

EP 0 585 943 B1

(A) LENGTH: 840 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

10

(A) NAME/KEY: CDS  
(B) LOCATION: 22..807

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

15

CCATTTCAAC TTTAACACAG C ATG ATC GAA ACA TAC AAC CAA ACT TCT CCC 51  
Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro  
1 5 10

20

CGA TCT GCG GCC ACT GGA CTG CCC ATC AGC ATG AAA ATT TTT ATG TAT 99  
Arg Ser Ala Ala Thr Gly Leu Pro Ile Ser Met Lys Ile Phe Met Tyr  
15 20 25

25

TTA CTT ACT GTT TTT CTT ATC ACC CAG ATG ATT GGG TCA GCA CTT TTT 147  
Leu Leu Thr Val Phe Leu Ile Thr Gln Met Ile Gly Ser Ala Leu Phe

30

35

40

45

50

55

EP 0 585 943 B1

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

EP 0 585 943 B1

(A) LENGTH: 261 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

10      Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly
        1           5           10           15
      Leu Pro Ile Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu
                20           25           30
15      Ile Thr Gln Met Ile Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg
        35           40           45
      Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val
        50           55           60
20      Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser
        65           70           75           80
      Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys
        85           90           95
25      Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu
        100          105          110
      Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser
        115          120          125
30      Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly
        130          135          140
      Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln
        145          150          155          160
35      Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr
        165          170          175
      Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser
        180          185          190
40      Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala
        195          200          205
      Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His
        210          215          220
45      Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn
        225          230          235          240
      Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe
        245          250          255
50      Gly Leu Leu Lys Leu
        260

```

55 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:



EP 0 585 943 B1

(A) LENGTH: 151 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

10 Phe Glu Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val  
1 5 10 15

15 Ile Ser Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu  
20 25 30

Lys Gly Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly  
35 40 45

20 Lys Gln Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln  
50 55 60

Val Thr Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile  
65 70 75 80

25 Ala Ser Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu  
85 90 95

Arg Ala Ala Asn Thr His Ser Ser Ala Lys Leu Gly Gly Gln Gln Ser  
100 105 110

30 Ile His Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe  
115 120 125

Val Asn Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr  
130 135 140

35 Ser Phe Gly Leu Leu Lys Leu  
145 150

(2) INFORMATION FOR SEQ ID NO:4:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 151 amino acids

(B) TYPE: amino acid

45

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

50

55

EP 0 585 943 B1

1 Phe Glu Met Gln Arg Gly Asp Glu Asp Pro Gln Ile Ala Ala His Val  
 5 Val Ser Glu Ala Asn Ser Asn Ala Ala Ser Val Leu Gln Trp Ala Lys  
 10 Lys Gly Tyr Tyr Thr Met Lys Ser Asn Leu Val Met Leu Glu Asn Gly  
 15 Val Thr Phe Cys Ser Asn Arg Glu Pro Ser Ser Gln Arg Pro Phe Ile  
 20 Val Gly Leu Trp Leu Lys Pro Ser Ile Gly Ser Glu Arg Ile Leu Leu  
 25 Lys Ala Ala Asn Thr His Ser Ser Ser Gln Leu Cys Glu Gln Gln Ser  
 30 Val His Leu Gly Gly Tyr Phe Glu Leu Gln Ala Gly Ala Ser Val Phe  
 35 Val Asn Val Thr Glu Ala Ser Gln Tyr Ile His Arg Val Gly Phe Ser  
 40 Ser Phe Gly Leu Leu Lys Leu  
 45  
 50  
 55

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 157 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

EP 0 585 943 B1

Val Arg Ser Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val  
1 5 10 15

Val Ala Asn Pro Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg  
20 25 30

Ala Asn Ala Leu Leu Ala Asn Gly Val Glu Leu Arg Asp Asn Gln Leu  
35 40 45

Val Val Pro Ser Glu Gly Leu Tyr Leu Ile Tyr Ser Gln Val Leu Phe  
50 55 60

Lys Gly Gln Gly Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile  
65 70 75 80

Ser Arg Ile Ala Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala  
85 90 95

Ile Lys Ser Pro Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys  
100 105 110

Pro Trp Tyr Glu Pro Ile Tyr Ile Gly Gly Val Phe Gln Leu Glu Lys  
115 120 125

Gly Asp Arg Leu Ser Ala Glu Ile Asn Arg Pro Asp Tyr Leu Asp Phe  
130 135 140

Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu  
145 150 155

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 155 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Pro Lys Met His Leu Ala His Ser Thr Leu Lys Pro Ala Ala His Leu  
1 5 10 15

Ile Asn Asp Pro Ser Lys Gln Asn Ser Leu Leu Trp Arg Ala Asn Thr  
20 25 30

Asp Arg Ala Phe Leu Gln Asp Gly Phe Ser Leu Ser Ser Asn Asn Ser  
35 40 45

Leu Leu Val Pro Thr Ser Gly Ile Tyr Phe Tyr Tyr Ser Gln Val Val  
50 55 60

Phe Ser Gly Lys Ala Tyr Ser Pro Lys Ala Thr Ser Ser Pro Ile Tyr  
65 70 75 80

**EP 0 585 943 B1**

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    | Leu | Ala | His | Glu | Val | Gln | Leu | Phe | Ser | Ser | Gln | Tyr | Pro | Phe | His | Val |
|    |     |     |     |     | 85  |     |     |     |     |     |     |     | 90  |     |     | 95  |
| 5  | Pro | Leu | Leu | Ser | Ser | Gln | Lys | Met | Val | Tyr | Pro | Gly | Leu | Gln | Glu | Pro |
|    |     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
|    | Trp | Leu | His | Ser | Met | Tyr | His | Gly | Ala | Ala | Phe | Gln | Leu | Thr | Gln | Gly |
|    |     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| 10 | Asp | Gln | Leu | Ser | Thr | His | Thr | Asp | Gly | Ile | Pro | His | Leu | Val | Leu | Ser |
|    |     | 130 |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
|    | Pro | Ser | Thr | Val | Phe | Phe | Gly | Ala | Gly | Ala | Leu |     |     |     |     |     |
|    |     | 145 |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     |     |

15 (2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Leu Asp Phe Ala Cys Asp Pro Asp Pro Arg Arg Leu Asp Lys Ile  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Leu Asp Phe Ala Cys Asp Pro Asp Pro Arg Tyr Leu Gln Val Ser  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 972 base pairs  
(B) TYPE: nucleic acid  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

EP 0 585 943 B1

GCTGGCTAAA GGAGCAGTTT CCCCACCCT ACACGCCTCC CCCACCGCAC CTCCTCCGCC 60  
 CTGTTCTCTGG GCCCCTCCCC TAGAGCCCTA GCTTGACCTA AGCTGCTTGC TGGTGGAGAG 120  
 5 CACACCATGG CCTCACCATT GACCCGCTTT CTGTCGCTGA ACCTGCTGCT GCTGGGTGAG 180  
 TCGATTATCC TGGGGAGTGG AGAAGCTAAG CCACAGGCAC CCGAACTCCG AATCTTTCCA 240  
 AAGAAAATGG ACGCCGAAC TGGTCAGAAG GTGGACCTGG TATGTGAAGT GTTGGGGTCC 300  
 10  
 GTTTCGCAAG GATGCTCTTG GCTCTTCCAG AACTCCAGCT CCAAACCTCC CCAGCCCACC 360  
 15 TTCGTTGTCT ATATGGCTTC ATCCCACAAC AAGATAACGT GGGACGAGAA GCTGAATTCTG 420  
 TCGAAACTGT TTTCTGCCAT GAGGGACACG AATAATAAGT ACGTTCTCAC CCTGAACAAG 480  
 TTCAGCAAGG AAAACGAAGG CTACTATTTC TGCTCAGTCA TCAGCAACTC GGTGATGTAC 540  
 20 TTCAGTTCTG TCGTGCCAGT CCTTCAGAAA GTGAACCTA CTACTACCAA GCCAGTGCTG 600  
 CGAACTCCCT CACCTGTGCA CCCTACCGGG ACATCTCAGC CCCAGAGACC AGAAGATTGT 660  
 CGGCCCCGTG GCTCAGTGAA GGGGACCGGA TTGGACTTCG CCTGTGATAT TTACATCTGG 720  
 25 GCACCCTTGG CCGGAATCTG CGTGGCCCTT CTGCTGTCCT TGATCATCAC TCTCATCTGC 780  
 TACCACAGGA GCCGAAAGCG TGTITGCAAA TGTCCCAGGC CGCTAGTCAG ACAGGAAGGC 840  
 AAGCCCAGAC CTTCAGAGAA AATTGTGTAA AATGGCACCG CCAGGAAGCT ACAACTACTA 900  
 30 CATGACTTCA GAGATCTCTT CTGCAAGAG GCCAGGCCCT CCTTTTCAA GTTTCCTGCT 960  
 GTCTTATGTA TT 972

(2) INFORMATION FOR SEQ ID NO:10:

35 (i) SEQUENCE CHARACTERISTICS:

40 (A) LENGTH: 249 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

50

55

EP 0 585 943 B1

Met Ala Ser Pro Leu Thr Arg Phe Leu Ser Leu Asn Leu Leu Leu Leu  
1 5 10 15

5 Gly Glu Ser Ile Ile Leu Gly Ser Gly Glu Ala Lys Pro Gln Ala Pro  
20 25 30

Glu Leu Arg Ile Phe Pro Lys Lys Met Asp Ala Glu Leu Gly Gln Lys  
35 40 45

10 Val Asp Leu Val Cys Glu Val Leu Gly Ser Val Ser Gln Gly Cys Ser  
50 55 60

Trp Leu Phe Gln Asn Ser Ser Ser Lys Leu Pro Gln Pro Thr Phe Val  
65 70 75 80

15 Val Tyr Met Ala Ser Ser His Asn Lys Ile Thr Trp Asp Glu Lys Leu  
85 90 95

Asn Ser Ser Lys Leu Phe Ser Ala Met Arg Asp Thr Asn Asn Lys Tyr  
100 105 110

20 Val Leu Thr Leu Asn Lys Phe Ser Lys Glu Asn Glu Gly Tyr Tyr Phe  
115 120 125

Cys Ser Val Ile Ser Asn Ser Val Met Tyr Phe Ser Ser Val Val Pro  
130 135 140

25 Val Leu Gln Lys Val Asn Ser Thr Thr Thr Lys Pro Val Leu Arg Thr  
145 150 155 160

Pro Ser Pro Val His Pro Thr Gly Thr Ser Gln Pro Gln Arg Pro Glu  
165 170 175

30

Asp Cys Arg Pro Arg Gly Ser Val Lys Gly Thr Gly Leu Asp Phe Ala  
180 185 190

35 Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Ile Cys Val Ala Leu  
195 200 205

Leu Leu Ser Leu Ile Ile Thr Leu Ile Cys Tyr His Arg Ser Arg Lys  
210 215 220

40 Arg Val Cys Lys Cys Pro Arg Pro Leu Val Arg Gln Glu Gly Lys Pro  
225 230 235 240

Arg Pro Ser Glu Lys Ile Val Asn Gly  
245

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 1060 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

55 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

EP 0 585 943 B1

|    |   |      |
|----|---|------|
|    | CGGCTCCCGC GCCGCCTCCC CTCGCGCCCG AGCTTCGAGC CAAGCAGCGT CCTGGGGAGC | 60   |
|    | GCGTCATGGC CTTACCAAGT ACCGCCTTGC TCCTGCCGCT GGCCTTGCTG CTCCACGCCG | 120  |
| 5  | CCAGGCCGAG CCAGTTCCGG GTGTGCGCGC TGGATCGGAC CTGGAACCTG GCGGAGACAG | 180  |
|    | TGGAGCTGAA GTGCCAGGTG CTGCTGTCCA ACCCGACGTC GGGCTGCTCG TGGCTCTTCC | 240  |
|    | AGCCGCGCGG CGCCGCGGCC AGTCCCACCT TCCTCCTATA CCTCTCCCAA AACAAGCCCA | 300  |
| 10 | AGGCGGCCGA GGGGCTGGAC ACCCAGCGGT TCTCGGGCAA GAGGTTGGGG GACACCTTCG | 360  |
|    | TCCTCACCCT GAGCGACTTC CGCCGAGAGA ACGAGGGCTA CTATTTCTGC TCGGCCCTGA | 420  |
|    | GCAACTCCAT CATGTACTTC AGCCACTTCG TGCCGGTCTT CCTGCCAGCG AAGCCCACCA | 480  |
| 15 | CGACGCCAGC GCCGCGACCA CCAACACCGG CGCCCACCAT CGCGTCGCAG CCCCTGTCCC | 540  |
|    | TGCGCCCAGA GGGGTGCCGG CCAGCGGCGG GGGGCGCAGT GCACACGAGG GGGCTGGACT | 600  |
|    | TCGCCTGTGA TATCTACATC TGGGCGCCCT TGGCCGGGAC TTGTGGGGTC CTTCTCCTGT | 660  |
| 20 | CACTGGTTAT CACCCTTTAC TGCAACCACA GGAACCGAAG ACGTGTTTGC AAATGTCCCC | 720  |
|    | GGCCTGTGGT CAAATCGGGA GACAAGCCCA GCCTTTCGGC GAGATACGTC TAACCCTGTG | 780  |
|    | CAACAGCCAC TACATTACTT CAAACTGAGA TCCTTCCTTT TGAGGGAGCA AGTCCTTCCC | 840  |
| 25 | TTTCATTTTT TCCAGTCTTC CTCCTGTGT ATTCAATCTC ATGATTATTA TTTTAGTGGG  | 900  |
|    | GGCGGGGTGG GAAAGATTAC TTTTCTTTA TGTGTTTGAC GGGAAACAAA ACTAGGTAAA  | 960  |
|    | ATCTACAGTA CACCACAAGG GTCACAATAC TGTTGTGCGC ACATCGCGGT AGGGCGTGGA | 1020 |
| 30 | AAGGGGCAGG CCAGAGCTAC CCGCAGAGTT CTCAGAATCA                       | 1060 |

(2) INFORMATION FOR SEQ ID NO:12:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 235 amino acids

(B) TYPE: amino acid

40

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

45

50

55

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu  
 1 5 10 15  
 5 His Ala Ala Arg Pro Ser Gln Phe Arg Val Ser Pro Leu Asp Arg Thr  
 20 25 30  
 Trp Asn Leu Gly Glu Thr Val Glu Leu Lys Cys Gln Val Leu Leu Ser  
 35 40 45  
 10 Asn Pro Thr Ser Gly Cys Ser Trp Leu Phe Gln Pro Arg Gly Ala Ala  
 50 55 60  
 Ala Ser Pro Thr Phe Leu Leu Tyr Leu Ser Gln Asn Lys Pro Lys Ala  
 65 70 75 80  
 15 Ala Glu Gly Leu Asp Thr Gln Arg Phe Ser Gly Lys Arg Leu Gly Asp  
 85 90 95  
 Thr Phe Val Leu Thr Leu Ser Asp Phe Arg Arg Glu Asn Glu Gly Tyr  
 100 105 110  
 20 Tyr Phe Cys Ser Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser His Phe  
 115 120 125  
 Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg  
 130 135 140  
 25 Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg  
 145 150 155 160  
 Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly  
 165 170 175  
 30 Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr  
 180 185 190  
 Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His  
 195 200 205  
 35 Arg Asn Arg Arg Arg Val Cys Lys Cys Pro Arg Pro Val Val Lys Ser  
 210 215 220  
 Gly Asp Lys Pro Ser Leu Ser Ala Arg Tyr Val  
 225 230 235  
 40

## (2) INFORMATION FOR SEQ ID NO:13:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GCGAAGCTTT CAGTCAGCAT GATAGAAACA

30



(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 30 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- 10 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

15 CGCTCTAGAT GTTCAGAGTT TGAGTAAGCC 30

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 39 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- 25 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

30 CGAAGCTTGG ATCCGAGGAG GTTGGACAAG ATAGAAGAT 39

Claims

- 35 1. An essentially purified and isolated nucleic acid comprising a sequence substantially as set forth in Figure 1 from nucleotide residues 160 to 787, or a sequence that encodes a protein having an amino acid sequence substantially as set forth in Figure 1 from amino acid residues 47 to 261, and further comprising a sequence encoding an extracellular domain of a type I membrane protein.
- 40 2. The essentially purified and isolated nucleic acid of claim 1 comprising a sequence encoding an extracellular domain of a type I membrane protein, which is a sequence encoding an extracellular domain of CD8 protein.
- 45 3. The essentially purified and isolated nucleic acid of claim 2 as contained in plasmid CDM7B<sup>+</sup> MC1061/p3-shgp39, as deposited with the American Type Culture Collection and assigned accession number 69049.
- 50 4. An essentially purified and isolated protein comprising a sequence substantially as set forth in Figure 1 from amino acid residues 47 to 261, and further comprising an extracellular domain of a type I membrane protein.
- 55 5. The essentially purified and isolated protein of claim 4 comprising an extracellular domain of a type I membrane protein, which is an extracellular domain of CD8 protein.
6. The essentially purified and isolated protein of claim 5 as produced by expression of plasmid CDM7B<sup>+</sup> MC1061/p3-shgp39, as deposited with the American Type Culture Collection and assigned accession number 69049.
7. An in vitro method of promoting B-cell proliferation comprising exposing activated B-cells to an effective concentration of at least one protein of claims 4 to 6.

8. An in vitro method of promoting B-cell proliferation comprising exposing B-cells to (i) an effective concentration of a protein of claims 4 to 6 and (ii) a costimulatory substance.
- 5 9. The method of claim 8 in which the costimulatory substance is an anti-immunoglobulin antibody.
- 10 10. The method of claim 9 in which the costimulatory substance is an antibody directed toward a B-cell antigen.
11. The method of claim 10 in which the B-cell antigen is CD20.
- 10 12. Use of at least one protein of the claims 4 to 6 for preparing a pharmaceutical composition suitable for augmenting the immune response of a subject.
13. A pharmaceutical composition comprising a therapeutically effective concentration of at least one protein of claims 4 to 6 in a suitable pharmacological carrier.
- 15 14. An in vitro method of promoting B-cell differentiation comprising exposing activated B-cells to an effective concentration of at least one protein of claims 4 to 6.
- 20 15. An in vitro method of promoting B-cell differentiation comprising exposing B-cells to (i) an effective concentration of a protein of claims 4 to 6 and (ii) a costimulatory substance.
16. The method of claim 15 in which the costimulatory substance is an anti-immunoglobulin antibody.
17. The method of claim 15 in which the costimulatory substance is an antibody directed toward a B-cell antigen.
- 25 18. The method of claim 15 in which the B-cell antigen is CD20.
19. An in vitro method of promoting the proliferation of cells that bear CD40 comprising exposing the cells to an effective concentration of a protein of claims 4 to 6.
- 30 20. An in vitro method of promoting the differentiation of cells that bear CD40 comprising exposing the cells to an effective concentration of a protein of claims 4 to 6.
21. The method of claim 19 or 20 in which the cells are sarcoma cells.
- 35 22. Use of at least one protein of claims 4 to 6 for preparing a pharmaceutical composition suitable for promoting B-cell proliferation.
23. The use of claim 22, wherein additionally a costimulatory substance is applied.
- 40 24. The use of claim 22 in which the costimulatory substance is an anti-immunoglobulin antibody.
25. The use of claim 24 in which the costimulatory substance is an antibody directed toward a B-cell antigen.
- 45 26. The use of claim 25 in which the B-cell antigen is CD20.
27. Use of at least one protein of claims 4 to 6 for preparing a pharmaceutical composition suitable for promoting B-cell differentiation.
- 50 28. The use of claim 27, wherein additionally a costimulatory substance is applied.
29. The use of claim 28 in which the costimulatory substance is an anti-immunoglobulin antibody.
30. The use of claim 28 in which the costimulatory substance is an antibody directed toward a B-cell antigen.
- 55 31. The use of claim 28 in which the B-cell antigen is CD20.
32. Use of a protein of claims 4 to 6 for preparing a pharmaceutical composition suitable for promoting the proliferation

and/or the differentiation of cells that bear CD40.

33. The use of claim 32 in which the cells are sarcoma cells.

5

# Patentansprüche

10

1. Im wesentlichen reine und isolierte Nukleinsäure, die eine Sequenz von Nukleotidrest 160 bis 787, wie sie im wesentlichen in Figur 1 beschrieben ist, oder eine Sequenz umfaßt, die für ein Protein mit einer Aminosäuresequenz von Aminosäurerest 47 bis 261 kodiert, wie sie im wesentlichen in Figur 1 beschrieben ist, und die zusätzlich eine Sequenz umfaßt, die für eine extrazelluläre Domäne eines Membranproteins vom Typ I kodiert.

15

2. Im wesentlichen gereinigte und isolierte Nukleinsäure nach Anspruch 1, umfassend eine Sequenz, die für eine extrazelluläre Domäne eines Membranproteins vom Typ I kodiert, nämlich eine Sequenz, die für eine extrazelluläre Domäne von CD8-Protein kodiert.

20

3. Im wesentlichen gereinigte und isolierte Nukleinsäure nach Anspruch 2, die in dem Plasmid CDM7B-MC1061/p3-shgp39 enthalten ist, welches bei der American Type Culture Collection hinterlegt wurde und die Hinterlegungsnr. 69049 erhalten hat.

25

4. Im wesentlichen gereinigtes und isoliertes Protein, das eine Sequenz von Aminosäurerest 47 bis 261 umfaßt, wie sie im wesentlichen in Figur 1 beschrieben ist, und das zusätzlich eine extrazelluläre Domäne eines Membranproteins vom Typ I umfaßt.

30

5. Im wesentlichen gereinigtes und isoliertes Protein nach Anspruch 4, das eine extrazelluläre Domäne eines Membranproteins vom Typ I, nämlich eine extrazelluläre Domäne von CD8-Protein, umfaßt.

6. Im wesentlichen gereinigtes und isoliertes Protein nach Anspruch 5, erhältlich durch Expression des bei der American Type Culture Collection hinterlegten Plasmids CDM7B-MC1061/p3-shgp39 mit der Hinterlegungsnummer 69049.

35

7. In vitro-Verfahren zur Förderung der B-Zellproliferation, wobei man aktivierte B-Zellen mit wenigstens einem Protein nach einem der Ansprüche 4 bis 6 in einer wirksamen Konzentration behandelt.

8. In vitro-Verfahren zur Förderung der B-Zellproliferation, wobei man B-Zellen mit (i) einem Protein nach einem der Ansprüche 4 bis 6 in einer wirksamen Konzentration und (ii) einer kostimulierenden Substanz behandelt.

9. Verfahren nach Anspruch 8, worin die kostimulierende Substanz ein Anti-Immunoglobulin-Antikörper ist.

40

10. Verfahren nach Anspruch 9, worin die kostimulierende Substanz ein gegen ein B-Zell-Antigen gerichteter Antikörper ist.

11. Verfahren nach Anspruch 10, worin das B-Zell-Antigen CD20 ist.

45

12. Verwendung wenigstens eines Proteins nach den Ansprüchen 4 bis 6 zur Herstellung eines pharmazeutischen Mittels, das zur Verstärkung der Immunreaktion eines Individuums geeignet ist.

50

13. Pharmazeutisches Mittel, umfassend eine therapeutisch wirksame Konzentration wenigstens eines Proteins nach den Ansprüchen 4 bis 6 in einem geeigneten pharmakologischen Träger.

14. In vitro-Verfahren zur Förderung der B-Zell-Differenzierung, wobei man aktivierte B-Zellen mit einer wirksamen Konzentration wenigstens eines Proteins nach den Ansprüchen 4 bis 6 behandelt.

55

15. In vitro-Verfahren zur Förderung der B-Zell-Differenzierung, wobei man B-Zellen mit (i) einer wirksamen Konzentration eines Proteins nach den Ansprüchen 4 bis 6 und (ii) einer kostimulierenden Substanz behandelt.

16. Verfahren nach Anspruch 15, worin die kostimulierende Substanz ein Anti-Immunoglobulin-Antikörper ist.

17. Verfahren nach Anspruch 15, worin die kostimulierende Substanz ein gegen ein B-Zell-Antigen gerichteter Antikörper ist.
18. Verfahren nach Anspruch 15, worin das B-Zell-Antigen CD20 ist.
19. In vitro-Verfahren zur Förderung der Proliferation von Zellen, die CD40 aufweisen, wobei man die Zellen mit einer wirksamen Konzentration eines Proteins der Ansprüche 4 bis 6 behandelt.
20. In vitro-Verfahren zur Förderung der Differenzierung von Zellen, die CD40 aufweisen, wobei man die Zellen mit einer wirksamen Konzentration eines Proteins der Ansprüche 4 bis 6 behandelt.
21. Verfahren nach Anspruch 19 oder 20, wobei die Zellen Sarkomzellen sind.
22. Verwendung wenigstens eines Proteins der Ansprüche 4 bis 6 zur Herstellung eines pharmazeutischen Mittels, das zur Förderung der B-Zell-Proliferation geeignet ist.
23. Verwendung nach Anspruch 22, wobei zusätzlich eine kostimulatorische Substanz zur Anwendung kommt.
24. Verwendung nach Anspruch 22, wobei die kostimulatorische Substanz ein Anti-Immunglobulin-Antikörper ist.
25. Verwendung nach Anspruch 24, wobei die kostimulatorische Substanz ein gegen ein B-Zell-Antigen gerichteter Antikörper ist.
26. Verwendung nach Anspruch 25, wobei das B-Zell-Antigen CD20 ist.
27. Verwendung wenigstens eines Proteins der Ansprüche 4 bis 6 zur Herstellung eines pharmazeutischen Mittels, das zur Förderung der B-Zell-Differenzierung geeignet ist.
28. Verwendung nach Anspruch 27, wobei zusätzlich eine kostimulatorische Substanz zur Anwendung kommt.
29. Verwendung nach Anspruch 28, wobei die kostimulatorische Substanz ein Anti-Immunglobulin-Antikörper ist.
30. Verwendung nach Anspruch 28, wobei die kostimulatorische Substanz ein gegen ein B-Zell-Antigen gerichteter Antikörper ist.
31. Verwendung nach Anspruch 28, wobei das B-Zell-Antigen CD20 ist.
32. Verwendung eines Proteins der Ansprüche 4 bis 6 zur Herstellung eines pharmazeutischen Mittels, das zur Förderung der Proliferation und/oder Differenzierung von Zellen geeignet ist, die CD40 aufweisen.
33. Verwendung nach Anspruch 32, wobei die Zellen Sarkomzellen sind.

#### Revendications

1. Acide nucléique essentiellement purifié et isolé comprenant une séquence substantiellement telle que décrite en Figure 1 à partir des résidus nucléotides 160 à 787, ou une séquence qui encode une protéine ayant une séquence d'acides aminés substantiellement telle que décrite en Figure 1 à partir des résidus acides aminés 47 à 261, et comprenant de plus une séquence encodant un domaine extracellulaire d'une protéine de membrane du type I.
2. Acide nucléique essentiellement purifié et isolé selon la revendication 1 comprenant une séquence encodant un domaine extracellulaire d'une protéine de membrane du type I, qui est une séquence encodant un domaine extracellulaire de la protéine CD8.
3. Acide nucléique essentiellement purifié et isolé selon la revendication 2 telle que contenue dans le plasmide CDM7B: MC1061/p3-shgp39, tel que déposé auprès de l'American Type Culture Collection et qui a reçu le numéro d'accès 69049.

4. Protéine essentiellement purifiée et isolée comprenant une séquence substantiellement telle que décrite en Figure 1 à partir des résidus acides aminés 47 à 261, et comprenant de plus un domaine extracellulaire d'une protéine de membrane du type I.
- 5 5. Protéine essentiellement purifiée et isolée selon la revendication 4 comprenant un domaine extracellulaire d'une protéine de membrane du type I, qui est un domaine extracellulaire de la protéine CD8.
6. Protéine essentiellement purifiée et isolée selon la revendication 5, telle que produite par expression du plasmide CDM7B- NC1061/p3-shgp39, telle que déposée auprès de l'American Type Culture Collection et qui a reçu le  
10 numéro d'accès 69049.
7. Méthode in vitro de promotion de la prolifération des cellules-B comprenant l'exposition des cellules-B activées à une concentration efficace d'au moins une protéine selon les revendications 4 à 6.
- 15 8. Méthode in vitro de promotion de la prolifération des cellules-B comprenant l'exposition des cellules-B à (i) une concentration efficace d'une protéine selon les revendications 4 à 6 et (ii) une substance costimulante.
9. Méthode selon la revendication 8 dans laquelle la substance costimulante est un anticorps anti-immunoglobuline.
- 20 10. Méthode selon la revendication 9 dans laquelle la substance costimulante est un anticorps dirigé vers un antigène de cellule-B.
11. Méthode selon la revendication 10 dans laquelle l'antigène de cellule-B est CD20.
- 25 12. Utilisation d'au moins une protéine selon les revendications 4 à 6 pour préparer une composition pharmaceutique appropriée pour augmenter la réponse immune d'un sujet.
13. Composition pharmaceutique comprenant une concentration thérapeutiquement efficace d'au moins une protéine selon les revendications 4 à 6 dans un porteur pharmacologique approprié.
- 30 14. Méthode in vitro de promotion de la différenciation des cellules-B comprenant l'exposition des cellules-B activées à une concentration efficace d'au moins une protéine selon les revendications 4 à 6.
15. Méthode in vitro de promotion de la différenciation des cellules-B comprenant l'exposition des cellules-B à (i) une  
35 concentration efficace d'une protéine selon les revendications 4 à 6 et (ii) une substance costimulante.
16. Méthode selon la revendication 15 dans laquelle la substance costimulante est un anticorps anti-immunoglobine.
17. Méthode selon la revendication 15 dans laquelle la substance costimulante est un anticorps dirigé vers un antigène  
40 de cellule-B.
18. Méthode selon la revendication 15 dans laquelle l'antigène de cellule-B est CD20.
19. Méthode in vitro de promotion de la prolifération des cellules qui portent CD40 comprenant l'exposition des cellules  
45 à une concentration efficace d'une protéine selon les revendications 4 à 6.
20. Méthode in vitro de promotion de la différenciation des cellules qui portent CD40 comprenant l'exposition des cellules à une concentration efficace d'une protéine selon les revendications 4 à 6.
- 50 21. Méthode selon la revendication 19 ou 20 dans laquelle les cellules sont des cellules de sarcome.
22. Utilisation d'au moins une protéine selon les revendications 4 à 6 pour préparer une composition pharmaceutique appropriée pour promouvoir la prolifération des cellules-B.
- 55 23. Utilisation selon la revendication 22, dans laquelle additionnellement une substance costimulante est appliquée.
24. Utilisation selon la revendication 22 dans laquelle la substance costimulante est un anticorps anti-immunoglobuline.

**EP 0 585 943 B1**

**25.** Utilisation selon la revendication 24 dans laquelle la substance costimulante est un anticorps dirigé vers un antigène des cellules-B.

**26.** Utilisation selon la revendication 25 dans laquelle l'antigène de cellules-B est CD20.

**27.** Utilisation d'au moins une protéine selon les revendications 4 à 6 pour préparer une composition pharmaceutique appropriée pour promouvoir la différenciation des cellules-B.

**28.** Utilisation selon la revendication 27, dans laquelle additionnellement une substance costimulante est appliquée.

**29.** Utilisation selon la revendication 28 dans laquelle la substance costimulante est un anticorps anti-immunoglobuline.

**30.** Utilisation selon la revendication 28 dans laquelle la substance costimulante est un anticorps dirigé vers un antigène de cellule-B.

**31.** Utilisation selon la revendication 28 dans laquelle l'antigène de cellule-B est CD20.

**32.** Utilisation d'une protéine selon les revendications 4 à 6 pour préparer une composition pharmaceutique appropriée pour promouvoir la prolifération et/ou la différenciation des cellules qui portent CD40.

**33.** Utilisation selon la revendication 32 dans laquelle les cellules sont des cellules de sarcome.

```

1      CCATTTCAACTTTTAACACAGCATGATCGAAACATACAACCAAACCTTCTCCC
1      MetIleGluThrTyrAsnGlnThrSerPro
      ---CHO---
52     CGATCTGCGGCCACTGGACTGCCCATCAGCATGAAAATTTTATGTATTTACTT
11     ArgSerAlaAlaThrGlyLeuProIleSerMetLysIlePheMetTyrLeuLeu

106    ACTGTTTTTCTTATCACCCAGATGATTGGGTCAGCACTTTTGTGCTGTGTATCTT
29     ThrValPheLeuIleThrGlnMetIleGlySerAlaLeuPheAlaValTyrLeu
      TM
160    CATAGAAGGTTGGACAAGATAGAAGATGAAAGGAATCTTCATGAAGATTTTGTA
47     HisArgArgLeuAspLysIleGluAspGluArgAsnLeuHisGluAspPheVal

214    TTCATGAAAACGATACAGAGATGCAACACAGGAGAAAGATCCTTATCCTTACTG
65     PheMetLysThrIleGlnArgCysAsnThrGlyGluArgSerLeuSerLeuLeu

268    AACTGTGAGGAGATTAAAGCCAGTTTGAAGGCTTTGTGAAGGATATAATGTTA
83     AsnCysGluGluIleLysSerGlnPheGluGlyPheValLysAspIleMetLeu

322    AACAAAGAGGAGACGAAGAAAGAAAACAGCTTTGAAATGCAAAAAGGTGATCAG
101    AsnLysGluGluThrLysLysGluAsnSerPheGluMetGlnLysGlyAspGln

376    AATCCTCAAATTGCGGCACATGTCTAAGTGAGGCCAGCAGTAAACAACATCT
119    AsnProGlnIleAlaAlaHisValIleSerGluAlaSerSerLysThrThrSer

430    GTGTTACAGTGGGCTGAAAAGGATACTACACCATGAGCAACAACCTTGGTAACC
137    ValLeuGlnTrpAlaGluLysGlyTyrTyrThrMetSerAsnAsnLeuValThr

484    CTGGAAAATGGGAAACAGCTGACCGTTAAAAGACAAGGACTCTATTATATCTAT
155    LeuGluAsnGlyLysGlnLeuThrValLysArgGlnGlyLeuTyrTyrIleTyr

538    GCCCAAGTCACCTTCTGTTCCAATCGGGAAGCTTCGAGTCAAGCTCCATTTATA
173    AlaGlnValThrPheCysSerAsnArgGluAlaSerSerGlnAlaProPheIle

592    GCCAGCCTCTGCCTAAAGTCCCCCGGTAGATTTCGAGAGAATCTTACTCAGAGCT
191    AlaSerLeuCysLeuLysSerProGlyArgPheGluArgIleLeuLeuArgAla

646    GCAAATACCCACAGTTCCGCCAAACCTTGCGGGCAACAATCCATTCACTTGGGA
209    AlaAsnThrHisSerSerAlaLysProCysGlyGlnGlnSerIleHisLeuGly

700    GGAGTATTTGAATTGCAACCAGGTGCTTCGGTGTGTGCAATGTGACTGATCCA
227    GlyValPheGluLeuGlnProGlyAlaSerValPheValAsnValThrAspPro
      ---CHO---
754    AGCCAAGTGAGCCATGGCACTGGCTTCACGTCCTTTGGCTTACTCAAACCTCTGA
245    SerGlnValSerHisGlyThrGlyPheThrSerPheGlyLeuLeuLysLeuEnd

808    ACAGTGTACCTTGCAGGCTGTGGTGGAGCTGA

```

Figure 1A

|        |         |         |         |         |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
|--------|---------|---------|---------|---------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| H-gp39 | F E E M | Q Q S S | K R R S | G G R   | D D T | Q E P | N D P | P P Q | Q O K | I A A | A A H | V V V | S S E | A A P | S S A | T A E | S V Q | L Q W | A A L | E K K | G G R | Y V   |
| M-gp39 | F E E M | Q Q S S | K R R S | G G R   | D D T | Q E P | N D P | P P Q | Q O K | I A A | A A H | V V V | S S E | A A P | S S A | T A E | S V Q | L Q W | A A L | E K K | G G R | Y V   |
| H-TNfa | F E E M | Q Q S S | K R R S | G G R   | D D T | Q E P | N D P | P P Q | Q O K | I A A | A A H | V V V | S S E | A A P | S S A | T A E | S V Q | L Q W | A A L | E K K | G G R | Y V   |
| H-TNfb | F E E M | Q Q S S | K R R S | G G R   | D D T | Q E P | N D P | P P Q | Q O K | I A A | A A H | V V V | S S E | A A P | S S A | T A E | S V Q | L Q W | A A L | E K K | G G R | Y V   |
| H-gp39 | Y T T M | S K S L | N S N A | N N Q   | V V V | T T M | E E S | L L L | E E S | N N S | G K K | Q Q L | T T V | V V V | R R R | O E E | G G L | Y Y Y | Q Q V | T T L | S S N | Y V   |
| M-gp39 | Y T T M | S K S L | N S N A | N N Q   | V V V | T T M | E E S | L L L | E E S | N N S | G K K | Q Q L | T T V | V V V | R R R | O E E | G G L | Y Y Y | Q Q V | T T L | S S N | Y V   |
| H-TNfa | Y T T M | S K S L | N S N A | N N Q   | V V V | T T M | E E S | L L L | E E S | N N S | G K K | Q Q L | T T V | V V V | R R R | O E E | G G L | Y Y Y | Q Q V | T T L | S S N | Y V   |
| H-TNfb | Y T T M | S K S L | N S N A | N N Q   | V V V | T T M | E E S | L L L | E E S | N N S | G K K | Q Q L | T T V | V V V | R R R | O E E | G G L | Y Y Y | Q Q V | T T L | S S N | Y V   |
| H-gp39 | R E E C | S S S S | S S S S | S S S S | A P P | F F F | I I V | A A S | L L W | G L L | K K K | L L K | S S P | G G S | R R S | F F E | L L L | L L L | R K K | N N K | S S S | S S S |
| M-gp39 | R E E C | S S S S | S S S S | S S S S | A P P | F F F | I I V | A A S | L L W | G L L | K K K | L L K | S S P | G G S | R R S | F F E | L L L | L L L | R K K | N N K | S S S | S S S |
| H-TNfa | R E E C | S S S S | S S S S | S S S S | A P P | F F F | I I V | A A S | L L W | G L L | K K K | L L K | S S P | G G S | R R S | F F E | L L L | L L L | R K K | N N K | S S S | S S S |
| H-TNfb | R E E C | S S S S | S S S S | S S S S | A P P | F F F | I I V | A A S | L L W | G L L | K K K | L L K | S S P | G G S | R R S | F F E | L L L | L L L | R K K | N N K | S S S | S S S |
| H-gp39 | A K L   | G C E   | G E G   | Q Q     | A E A | E E A | K P W | Y E E | Q S S | H H Y | L L G | G G V | F F E | L L L | O P A | G G G | A A S | V V L | F F S | N N E | T T T | T T T |
| M-gp39 | A K L   | G C E   | G E G   | Q Q     | A E A | E E A | K P W | Y E E | Q S S | H H Y | L L G | G G V | F F E | L L L | O P A | G G G | A A S | V V L | F F S | N N E | T T T | T T T |
| H-TNfa | A K L   | G C E   | G E G   | Q Q     | A E A | E E A | K P W | Y E E | Q S S | H H Y | L L G | G G V | F F E | L L L | O P A | G G G | A A S | V V L | F F S | N N E | T T T | T T T |
| H-TNfb | A K L   | G C E   | G E G   | Q Q     | A E A | E E A | K P W | Y E E | Q S S | H H Y | L L G | G G V | F F E | L L L | O P A | G G G | A A S | V V L | F F S | N N E | T T T | T T T |
| H-gp39 | D E A   | S S S   | O Q Y   | H H     | S S S | O Q Y | H H   | S S S | O Q Y | H H   | S S S | O Q Y | H H   | S S S | O Q Y | H H   | S S S | O Q Y | H H   | S S S | O Q Y | H H   |
| M-gp39 | D E A   | S S S   | O Q Y   | H H     | S S S | O Q Y | H H   | S S S | O Q Y | H H   | S S S | O Q Y | H H   | S S S | O Q Y | H H   | S S S | O Q Y | H H   | S S S | O Q Y | H H   |
| H-TNfa | D E A   | S S S   | O Q Y   | H H     | S S S | O Q Y | H H   | S S S | O Q Y | H H   | S S S | O Q Y | H H   | S S S | O Q Y | H H   | S S S | O Q Y | H H   | S S S | O Q Y | H H   |
| H-TNfb | D E A   | S S S   | O Q Y   | H H     | S S S | O Q Y | H H   | S S S | O Q Y | H H   | S S S | O Q Y | H H   | S S S | O Q Y | H H   | S S S | O Q Y | H H   | S S S | O Q Y | H H   |

Figure 1B






FIGURE 2 A,B,C




FIGURE 3 A-F




Figure 4




Figure 5




Figure 6 A

B




Figure 6B

```

1 GCTGGCTAAA GGAGCAGTTT CCCCAGCCCT ACACGCCTCC CCCACCGCAC
51 CTCCTCCGCC CTGTTCTTGG GCCCCTCCCC TAGAGCCCTA GCTTGACCTA
101 AGCTGCTTGC TGGTGGAGAG CACACCATGG CCTCACCGTT GACCCGCTTT
151 CTGTCGCTGA ACCTGCTGCT GCTGGGTGAG TCGATTATCC TGGGGAGTGG
201 AGAAGCTAAG CCACAGGCAC CCGAACTCCG AATCTTTCCA AAGAAAATGG
251 ACGCCGAACT TGGTCAGAAG GTGGACCTGG TATGTGAAGT GTTGGGGTCC
301 GTTTCGCAAG GATGCTCTTG GCTCTTCCAG AACTCCAGCT CCAAACCTCC
351 CCAGCCCACC TTCGTTGTCT ATATGGCTTC ATCCCACAAC AAGATAACGT
401 GGGACGAGAA GCTGAATTCT TCGAAACTGT TTTCTGCCAT GAGGGACACG
451 AATAATAAGT ACGTCTCTAC CCTGAACAAG TTCAGCAAGG AAAACGAAGG
501 CTACTATTTC TGCTCAGTCA TCAGCAACTC GGTGATGTAC TTCAGTTCTG
551 TCGTGCCAGT CCTTCAGAAA GTGAACTCTA CTACTACCAA GCCAGTGCTG
601 CGAACTCCCT CACCTGTGCA CCCTACCGGG ACATCTCAGC CCCAGAGACC
651 AGAAGATTGT CGGCCCCGTG GCTCAGTGAA GGGGACCGGA TTGGACTTCG
701 CCTGTGATAT TTACATCTGG GCACCCTTGG CCGGAATCTG CGTGGCCCTT
751 CTGCTGTCCCT TGATCATCAC TCTCATCTGC TACCACAGGA GCCGAAAGCG
801 TGTTTGCAAA TGTCCAGGC CGCTAGTCAG ACAGGAAGGC AAGCCCAGAC
851 CTTCAGAGAA AATTGTGTAA AATGGCACCG CCAGGAAGCT ACAACTACTA
901 CATGACTTCA GAGATCTCTT CTTGCAAGAG GCCAGGCCCT CCTTTTTCAA
951 GTTTCCTGCT GTCTTATGTA TT

1 MASPLTRFLS LNLILLGESI ILGSGEAKPQ APELRIFPKK MDAELGQKVD
51 LVCEVLGSVS QGCSWLFQNS SSKLPQPTFV VYMASSHNKI TWDEKLNSSK
101 LFSAMRDTNN KYVLTNLKFS KENEGYYFCS VISNSVMYFS SVVPVLQKVN
151 STTTKPVLRT PSPVHPTGTS QPQRPEDCRP RGSVKGTGLD FACDIYIWAP
201 LAGICVALLL SLIITLICYP RSRKRVCKCP RPLVRQEGKP RPSEKIV*NG

```

Figure 7

```

1 CGGCTCCCGC GCCGCCTCCC CTCGCGCCCG AGCTTCGAGC CAAGCAGCGT
51 CCTGGGGAGC GCGTCATGGC CTTACCAGTG ACCGCCTTGC TCCTGCCGCT
101 GGCCTTGCTG CTCCACGCCG CCAGGCCGAG CCAGTTCCGG GTGTGCCCGC
151 TGGATCGGAC CTGGAACCTG GCGGAGACAG TGGAGCTGAA GTGCCAGGTG
201 CTGCTGTCCA ACCCGACGTC GGGCTGCTCG TGGCTCTTCC AGCCGCGCGG
251 CGCCGCCGCC AGTCCCACCT TCCTCCTATA CCTCTCCCAA AACAAGCCCA
301 AGGCGGCCGA GGGGCTGGAC ACCCAGCGGT TCTCGGGCAA GAGGTTGGGG
351 GACACCTTCG TCCTCACCTT GAGCGACTTC CGCCGAGAGA ACGAGGGCTA
401 CTATTTCTGC TCGGCCCTGA GCAACTCCAT CATGTACTTC AGCCACTTCG
451 TGCCGGTCTT CCTGCCAGCG AAGCCCACCA CGACGCCAGC GCCGCGACCA
501 CCAACACCGG CGCCCACCAT CGCGTCGCAG CCCCTGTCCC TGCGCCCAGA
551 GGCCTGCCGG CCAGCGGCGG GGGGCGCAGT GCACACGAGG GGGCTGGACT
601 TCGCCTGTGA TATCTACATC TGGGCGCCCT TGGCCGGGAC TTGTGGGGTC
651 CTTCTCCTGT CACTGGTTAT CACCCTTTAC TGCAACCACA GGAACCGAAG
701 ACGTGTTCG AAATGTCCCC GGCCTGTGGT CAAATCGGGA GACAAGCCCA
751 GCCTTTCGGC GAGATACGTC TAACCCTGTG CAACAGCCAC TACATTACTT
801 CAAACTGAGA TCCTTCCTTT TGAGGGAGCA AGTCCTTCCC TTTTATTTTT
851 TCCAGTCTTC CTCCCTGTGT ATTCATTCTC ATGATTATTA TTTTAGTGGG
901 GCGGGGGTGG GAAAGATTAC TTTTCTTTA TGTGTTTGAC GGGAAACAAA

951 ACTAGGTAAA ATCTACAGTA CACCACAAGG GTCACAATAC TGTTGTGCGC
1001 ACATCGCGGT AGGGCGTGGA AAGGGGCAGG CCAGAGCTAC CCGCAGAGTT
1051 CTCAGAATCA

1 MALPVTALLL PLALLLHAAR PSQFRVSPLD RTWNLGETVE LKQVLLSNP
51 TSGCSWLFQP RGAAASPTFL LYLSQNKPKA AEGLDTQRFS GKRLGDTFVL
101 TLSDFRRENE GYFFCSALSN SIMYFSHFVP VFLPAKPTTT PAPRPPTPAP
151 TIASQPLSLR PEACRPAAGG AVHTRGLDFA CDIYIWAPLA GTCGVLLLSL
201 VITLYCNHRN RRRVCKCPRP VVKSGDKPSL SARYV*

```

Figure 8



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**